MXPA99010961A - Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-&bgr;1 - Google Patents
Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-&bgr;1Info
- Publication number
- MXPA99010961A MXPA99010961A MXPA/A/1999/010961A MX9910961A MXPA99010961A MX PA99010961 A MXPA99010961 A MX PA99010961A MX 9910961 A MX9910961 A MX 9910961A MX PA99010961 A MXPA99010961 A MX PA99010961A
- Authority
- MX
- Mexico
- Prior art keywords
- carbon atoms
- tetrahydropyridine
- ethyl
- group
- phenyl
- Prior art date
Links
- -1 4-substituted tetrahydropyridines Chemical class 0.000 title claims description 72
- 239000003814 drug Substances 0.000 title claims description 8
- 229940079593 drugs Drugs 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 12
- 230000001413 cellular Effects 0.000 claims abstract description 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 82
- 239000000203 mixture Substances 0.000 claims description 73
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 53
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 53
- 238000002360 preparation method Methods 0.000 claims description 40
- 239000011780 sodium chloride Substances 0.000 claims description 29
- 150000003839 salts Chemical class 0.000 claims description 28
- 102100014320 TGFB1 Human genes 0.000 claims description 26
- 108010037805 Transforming growth factor beta-1 Proteins 0.000 claims description 26
- 239000012453 solvate Substances 0.000 claims description 20
- 229910052739 hydrogen Inorganic materials 0.000 claims description 18
- 239000001257 hydrogen Substances 0.000 claims description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
- 125000003545 alkoxy group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 14
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 11
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 125000003163 2-(2-naphthyl)ethyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(C([H])=C([H])C2=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 8
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 5
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 206010024324 Leukaemias Diseases 0.000 claims description 4
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 230000001154 acute Effects 0.000 claims description 4
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 4
- 230000001640 apoptogenic Effects 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 4
- 230000001684 chronic Effects 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 201000009910 diseases by infectious agent Diseases 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 4
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 claims description 3
- 230000002159 abnormal effect Effects 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 230000032677 cell aging Effects 0.000 claims description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000007502 Anemia Diseases 0.000 claims description 2
- 206010002383 Angina pectoris Diseases 0.000 claims description 2
- 208000008637 Anti-Glomerular Basement Membrane Disease Diseases 0.000 claims description 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 2
- 206010003225 Arteriospasm coronary Diseases 0.000 claims description 2
- 206010003284 Arthropathy Diseases 0.000 claims description 2
- 206010003441 Asbestosis Diseases 0.000 claims description 2
- 208000006673 Asthma Diseases 0.000 claims description 2
- 206010004661 Biliary cirrhosis primary Diseases 0.000 claims description 2
- 208000010392 Bone Fractures Diseases 0.000 claims description 2
- 206010007554 Cardiac failure Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000003890 Coronary Vasospasm Diseases 0.000 claims description 2
- 208000000718 Duodenal Ulcer Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010018620 Goodpasture's syndrome Diseases 0.000 claims description 2
- 206010019280 Heart failure Diseases 0.000 claims description 2
- 208000006454 Hepatitis Diseases 0.000 claims description 2
- 201000001971 Huntington's disease Diseases 0.000 claims description 2
- 102000004877 Insulin Human genes 0.000 claims description 2
- 108090001061 Insulin Proteins 0.000 claims description 2
- 208000009883 Joint Disease Diseases 0.000 claims description 2
- 208000001083 Kidney Disease Diseases 0.000 claims description 2
- 206010025135 Lupus erythematosus Diseases 0.000 claims description 2
- 206010027476 Metastasis Diseases 0.000 claims description 2
- 208000010125 Myocardial Infarction Diseases 0.000 claims description 2
- 208000003067 Myocardial Ischemia Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010033649 Pancreatitis chronic Diseases 0.000 claims description 2
- 208000003055 Prion Disease Diseases 0.000 claims description 2
- 206010040047 Sepsis Diseases 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims description 2
- 206010061367 Spinal cord disease Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- 206010043561 Thrombocytopenic purpura Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- WJJYZXPHLSLMGE-UHFFFAOYSA-N Xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 230000002155 anti-virotic Effects 0.000 claims description 2
- 201000001320 atherosclerosis Diseases 0.000 claims description 2
- 230000001363 autoimmune Effects 0.000 claims description 2
- 201000005000 autoimmune gastritis Diseases 0.000 claims description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
- 125000005111 carboxyalkoxy group Chemical group 0.000 claims description 2
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims description 2
- 201000011634 coronary artery vasospasm Diseases 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 claims description 2
- 201000003883 cystic fibrosis Diseases 0.000 claims description 2
- 230000001419 dependent Effects 0.000 claims description 2
- 230000002327 eosinophilic Effects 0.000 claims description 2
- 230000011132 hemopoiesis Effects 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 230000003902 lesions Effects 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 201000003793 myelodysplastic syndrome Diseases 0.000 claims description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 150000002829 nitrogen Chemical group 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 201000002728 primary biliary cirrhosis Diseases 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 210000002345 respiratory system Anatomy 0.000 claims description 2
- 200000000008 restenosis Diseases 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000010001 silicosis Diseases 0.000 claims description 2
- 125000005504 styryl group Chemical group 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 210000001519 tissues Anatomy 0.000 claims description 2
- 201000006704 ulcerative colitis Diseases 0.000 claims description 2
- 125000004429 atoms Chemical group 0.000 claims 3
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims 2
- CPNOPIRQIVSHKK-UHFFFAOYSA-N 1-[2-[4-(cyclohexen-1-yl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3CCCCC=3)CC=2)=C1 CPNOPIRQIVSHKK-UHFFFAOYSA-N 0.000 claims 1
- XCZKKZXWDBOGPA-UHFFFAOYSA-N 2-phenylbenzene-1,4-diol Chemical compound OC1=CC=C(O)C(C=2C=CC=CC=2)=C1 XCZKKZXWDBOGPA-UHFFFAOYSA-N 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 claims 1
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- 239000000047 product Substances 0.000 description 39
- 239000002904 solvent Substances 0.000 description 35
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 31
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 28
- 229940099456 Transforming Growth Factor Beta 1 Drugs 0.000 description 25
- 239000000243 solution Substances 0.000 description 25
- PMZURENOXWZQFD-UHFFFAOYSA-L na2so4 Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
- 206010059512 Apoptosis Diseases 0.000 description 21
- 230000006907 apoptotic process Effects 0.000 description 21
- 210000004027 cells Anatomy 0.000 description 21
- 229910052938 sodium sulfate Inorganic materials 0.000 description 20
- 235000011152 sodium sulphate Nutrition 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 16
- 239000003921 oil Substances 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M NaHCO3 Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 13
- IKHGUXGNUITLKF-UHFFFAOYSA-N acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- WVHBEIJGAINUBW-UHFFFAOYSA-N hydron;1-(2-naphthalen-2-ylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine;chloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WVHBEIJGAINUBW-UHFFFAOYSA-N 0.000 description 12
- 239000002609 media Substances 0.000 description 12
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
- NMWSKOLWZZWHPL-UHFFFAOYSA-N 3-chlorobiphenyl Chemical group ClC1=CC=CC(C=2C=CC=CC=2)=C1 NMWSKOLWZZWHPL-UHFFFAOYSA-N 0.000 description 11
- IFYKRMQORZOMNY-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCNCC=2)=C1 IFYKRMQORZOMNY-UHFFFAOYSA-N 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 10
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 239000012091 fetal bovine serum Substances 0.000 description 9
- YYLLIJHXUHJATK-UHFFFAOYSA-N Cyclohexyl acetate Chemical compound CC(=O)OC1CCCCC1 YYLLIJHXUHJATK-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 241000700159 Rattus Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000001184 potassium carbonate Substances 0.000 description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 229940053128 Nerve Growth Factor Drugs 0.000 description 5
- 102000015336 Nerve Growth Factor Human genes 0.000 description 5
- 108010025020 Nerve Growth Factor Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000008079 hexane Substances 0.000 description 5
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 5
- 230000000861 pro-apoptotic Effects 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 210000000188 Diaphragm Anatomy 0.000 description 4
- 210000002966 Serum Anatomy 0.000 description 4
- 229960004528 Vincristine Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000002424 anti-apoptotic Effects 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000000663 muscle cells Anatomy 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 125000004853 tetrahydropyridinyl group Chemical class N1(CCCC=C1)* 0.000 description 4
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 3
- YHPMRWZVIQTSFZ-UHFFFAOYSA-N 3,5-difluoro-2-(2-fluorophenyl)pyridine Chemical compound FC1=CC(F)=CN=C1C1=CC=CC=C1F YHPMRWZVIQTSFZ-UHFFFAOYSA-N 0.000 description 3
- 229960000583 Acetic Acid Drugs 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K Aluminium chloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000006947 Histones Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- JNSBEPKGFVENFS-UHFFFAOYSA-N [2-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1C(F)(F)F JNSBEPKGFVENFS-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 230000000875 corresponding Effects 0.000 description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- LYDPETMRVJXFJJ-UHFFFAOYSA-N 1-(2,2-diphenylethyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC=2)=C1 LYDPETMRVJXFJJ-UHFFFAOYSA-N 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DNJYJMDQLURVBB-UHFFFAOYSA-N 2-(2-bromoethyl)naphthalene Chemical compound C1=CC=CC2=CC(CCBr)=CC=C21 DNJYJMDQLURVBB-UHFFFAOYSA-N 0.000 description 2
- FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 2
- 210000004369 Blood Anatomy 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate dianion Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N Methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N Sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N Trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- BPLKQGGAXWRFOE-UHFFFAOYSA-M Trimethylsulfoxonium iodide Chemical compound [I-].C[S+](C)(C)=O BPLKQGGAXWRFOE-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 238000003782 apoptosis assay Methods 0.000 description 2
- 238000000889 atomisation Methods 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- QUXHCILOWRXCEO-UHFFFAOYSA-M magnesium;butane;chloride Chemical compound [Mg+2].[Cl-].CCC[CH2-] QUXHCILOWRXCEO-UHFFFAOYSA-M 0.000 description 2
- QMMFVYPAHWMCMS-UHFFFAOYSA-N methyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N methylphenylketone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000003891 oxalate salts Chemical class 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 230000001575 pathological Effects 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000005522 programmed cell death Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000003638 reducing agent Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 2
- OGTSHGYHILFRHD-UHFFFAOYSA-N (4-fluorophenyl)-phenylmethanone Chemical compound C1=CC(F)=CC=C1C(=O)C1=CC=CC=C1 OGTSHGYHILFRHD-UHFFFAOYSA-N 0.000 description 1
- UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-Trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
- 150000008083 1,2,3,6-tetrahydropyridines Chemical class 0.000 description 1
- KVNYFPKFSJIPBJ-UHFFFAOYSA-N 1,2-diethylbenzene Chemical compound CCC1=CC=CC=C1CC KVNYFPKFSJIPBJ-UHFFFAOYSA-N 0.000 description 1
- VNUPRKZUPUBXOD-UHFFFAOYSA-N 1,2-dimethoxyethane;1,4-dioxane Chemical compound COCCOC.C1COCCO1 VNUPRKZUPUBXOD-UHFFFAOYSA-N 0.000 description 1
- SEZHLKZEWYFCRB-UHFFFAOYSA-N 1,2-dimethoxyethane;oxolane Chemical compound C1CCOC1.COCCOC SEZHLKZEWYFCRB-UHFFFAOYSA-N 0.000 description 1
- YJTKZCDBKVTVBY-UHFFFAOYSA-N 1,3-Diphenylbenzene Chemical group C1=CC=CC=C1C1=CC=CC(C=2C=CC=CC=2)=C1 YJTKZCDBKVTVBY-UHFFFAOYSA-N 0.000 description 1
- AFZZYIJIWUTJFO-UHFFFAOYSA-N 1,3-diethylbenzene Chemical compound CCC1=CC=CC(CC)=C1 AFZZYIJIWUTJFO-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IBIYQZBPDLOXIV-UHFFFAOYSA-N 1-(1,1-dimethoxyethyl)-4-[2-(trifluoromethyl)phenyl]benzene Chemical compound C1=CC(C(C)(OC)OC)=CC=C1C1=CC=CC=C1C(F)(F)F IBIYQZBPDLOXIV-UHFFFAOYSA-N 0.000 description 1
- MKWYOCFXHZSUNC-UHFFFAOYSA-N 1-(2-bromoethyl)-2-phenylbenzene Chemical compound BrCCC1=CC=CC=C1C1=CC=CC=C1 MKWYOCFXHZSUNC-UHFFFAOYSA-N 0.000 description 1
- FHIQDCJGLXOVAF-UHFFFAOYSA-N 1-(3,3-diphenylpropyl)-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC(C=3C=CC=CC=3)C=3C=CC=CC=3)CC=2)=C1 FHIQDCJGLXOVAF-UHFFFAOYSA-N 0.000 description 1
- YLHKGMASJSOHIB-UHFFFAOYSA-N 1-(4-butylphenyl)-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1=CC(CCCC)=CC=C1C(=O)CN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 YLHKGMASJSOHIB-UHFFFAOYSA-N 0.000 description 1
- OUCNIIPZAQATMO-UHFFFAOYSA-N 1-(4-phenoxyphenyl)-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CC(=O)C=3C=CC(OC=4C=CC=CC=4)=CC=3)CC=2)=C1 OUCNIIPZAQATMO-UHFFFAOYSA-N 0.000 description 1
- VWYGJOZLKMQCMH-UHFFFAOYSA-N 1-(4-phenylphenyl)-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CC(=O)C=3C=CC(=CC=3)C=3C=CC=CC=3)CC=2)=C1 VWYGJOZLKMQCMH-UHFFFAOYSA-N 0.000 description 1
- BYERKALFEPKLGF-UHFFFAOYSA-N 1-(4-tert-butylphenyl)-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1=CC(C(C)(C)C)=CC=C1C(=O)CN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 BYERKALFEPKLGF-UHFFFAOYSA-N 0.000 description 1
- XZGLNPZAUPLHST-UHFFFAOYSA-N 1-[2-(3,4-diethylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine;hydrochloride Chemical compound Cl.C1=C(CC)C(CC)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 XZGLNPZAUPLHST-UHFFFAOYSA-N 0.000 description 1
- WFCIDJRHEYDHPO-UHFFFAOYSA-N 1-[2-(3-methyl-4-pentylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound C1=C(C)C(CCCCC)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 WFCIDJRHEYDHPO-UHFFFAOYSA-N 0.000 description 1
- PVWFMJXSOCUVLF-UHFFFAOYSA-N 1-[2-(4-methyl-3-pentylphenyl)ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound C1=C(C)C(CCCCC)=CC(CCN2CC=C(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1 PVWFMJXSOCUVLF-UHFFFAOYSA-N 0.000 description 1
- UIJANJBMUXHFTF-UHFFFAOYSA-N 1-[2-[3-methyl-4-(2-methylpropyl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound C1=C(C)C(CC(C)C)=CC=C1CCN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 UIJANJBMUXHFTF-UHFFFAOYSA-N 0.000 description 1
- LEPLKKREOGXQSX-UHFFFAOYSA-N 1-[2-[4-(cyclohexen-1-yl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=CC(=CC=3)C=3CCCCC=3)CC=2)=C1 LEPLKKREOGXQSX-UHFFFAOYSA-N 0.000 description 1
- BWXLZOYBJVKNAN-UHFFFAOYSA-N 1-[2-[4-methyl-3-(2-methylpropyl)phenyl]ethyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound C1=C(C)C(CC(C)C)=CC(CCN2CC=C(CC2)C=2C=C(C=CC=2)C(F)(F)F)=C1 BWXLZOYBJVKNAN-UHFFFAOYSA-N 0.000 description 1
- UDDHPDJWOQQARE-UHFFFAOYSA-N 1-[2-methyl-2-[4-(2-methylpropyl)phenyl]propyl]-4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridine Chemical compound C1=CC(CC(C)C)=CC=C1C(C)(C)CN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 UDDHPDJWOQQARE-UHFFFAOYSA-N 0.000 description 1
- ONMAKBNJSZALNM-UHFFFAOYSA-N 1-[4-(2-methylpropyl)phenyl]-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone;hydrochloride Chemical compound Cl.C1=CC(CC(C)C)=CC=C1C(=O)CN1CC=C(C=2C=C(C=CC=2)C(F)(F)F)CC1 ONMAKBNJSZALNM-UHFFFAOYSA-N 0.000 description 1
- KMECTPOOKOIPPB-UHFFFAOYSA-N 1-[4-(3-chlorophenyl)phenyl]-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CC(=O)C=3C=CC(=CC=3)C=3C=C(Cl)C=CC=3)CC=2)=C1 KMECTPOOKOIPPB-UHFFFAOYSA-N 0.000 description 1
- AUELMBHRNDFANV-UHFFFAOYSA-N 1-[4-(4-chlorophenyl)phenyl]-2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]ethanone Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CC(=O)C=3C=CC(=CC=3)C=3C=CC(Cl)=CC=3)CC=2)=C1 AUELMBHRNDFANV-UHFFFAOYSA-N 0.000 description 1
- MLEGMEBCXGDFQT-UHFFFAOYSA-N 1-benzylpiperidin-2-one Chemical compound O=C1CCCCN1CC1=CC=CC=C1 MLEGMEBCXGDFQT-UHFFFAOYSA-N 0.000 description 1
- SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
- RWXUNIMBRXGNEP-UHFFFAOYSA-N 1-bromo-2-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC=C1Br RWXUNIMBRXGNEP-UHFFFAOYSA-N 0.000 description 1
- OFMVBOQHPIGOIN-UHFFFAOYSA-N 1-bromo-4-(1,1-dimethoxyethyl)benzene Chemical compound COC(C)(OC)C1=CC=C(Br)C=C1 OFMVBOQHPIGOIN-UHFFFAOYSA-N 0.000 description 1
- RUYZJEIKQYLEGZ-UHFFFAOYSA-N 1-fluoro-4-phenylbenzene Chemical group C1=CC(F)=CC=C1C1=CC=CC=C1 RUYZJEIKQYLEGZ-UHFFFAOYSA-N 0.000 description 1
- NQVHSBDSEAYZOO-UHFFFAOYSA-N 1-methyl-2-pentylbenzene Chemical compound CCCCCC1=CC=CC=C1C NQVHSBDSEAYZOO-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- RPSRZPOMRDDSPQ-UHFFFAOYSA-N 2-(1-benzyl-3,6-dihydro-2H-pyridin-4-yl)-6-chloropyridine Chemical compound ClC1=CC=CC(C=2CCN(CC=3C=CC=CC=3)CC=2)=N1 RPSRZPOMRDDSPQ-UHFFFAOYSA-N 0.000 description 1
- PMOSJSPFNDUAFY-UHFFFAOYSA-N 2-(4-bromophenyl)ethanol Chemical compound OCCC1=CC=C(Br)C=C1 PMOSJSPFNDUAFY-UHFFFAOYSA-N 0.000 description 1
- OSKZYKATAHBWQX-UHFFFAOYSA-N 2-(6,7-dimethoxynaphthalen-2-yl)acetic acid Chemical compound C1=C(CC(O)=O)C=C2C=C(OC)C(OC)=CC2=C1 OSKZYKATAHBWQX-UHFFFAOYSA-N 0.000 description 1
- KETGYOYWMXWALE-UHFFFAOYSA-N 2-[4-(3-chlorophenyl)phenyl]acetyl bromide Chemical compound ClC1=CC=CC(C=2C=CC(CC(Br)=O)=CC=2)=C1 KETGYOYWMXWALE-UHFFFAOYSA-N 0.000 description 1
- RVYCZHFEONFOKD-UHFFFAOYSA-N 2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-1-[4-[2-(trifluoromethyl)phenyl]phenyl]ethanone;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCN(CC(=O)C=3C=CC(=CC=3)C=3C(=CC=CC=3)C(F)(F)F)CC=2)=C1 RVYCZHFEONFOKD-UHFFFAOYSA-N 0.000 description 1
- IODODKJMIYKTFQ-UHFFFAOYSA-N 2-[4-[3-(trifluoromethyl)phenyl]-3,6-dihydro-2H-pyridin-1-yl]-1-[4-[4-(trifluoromethyl)phenyl]phenyl]ethanone;hydrochloride Chemical compound Cl.C1=CC(C(F)(F)F)=CC=C1C1=CC=C(C(=O)CN2CC=C(CC2)C=2C=C(C=CC=2)C(F)(F)F)C=C1 IODODKJMIYKTFQ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- WPWMYNBPYHSLIR-UHFFFAOYSA-N 2-chloro-6-(1,2,3,6-tetrahydropyridin-4-yl)pyridine Chemical compound ClC1=CC=CC(C=2CCNCC=2)=N1 WPWMYNBPYHSLIR-UHFFFAOYSA-N 0.000 description 1
- YFEODRYLGVDDDC-UHFFFAOYSA-N 2-chloro-6-(1,2,3,6-tetrahydropyridin-4-yl)pyridine;hydrochloride Chemical compound Cl.ClC1=CC=CC(C=2CCNCC=2)=N1 YFEODRYLGVDDDC-UHFFFAOYSA-N 0.000 description 1
- LAXBNTIAOJWAOP-UHFFFAOYSA-N 2-chlorobiphenyl Chemical group ClC1=CC=CC=C1C1=CC=CC=C1 LAXBNTIAOJWAOP-UHFFFAOYSA-N 0.000 description 1
- SVDDJQGVOFZBNX-UHFFFAOYSA-N 2-chloroethyl carbonochloridate Chemical compound ClCCOC(Cl)=O SVDDJQGVOFZBNX-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K 2qpq Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- BZQGAPWJKAYCHR-UHFFFAOYSA-N 3,3-diphenylpropanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C1=CC=CC=C1 BZQGAPWJKAYCHR-UHFFFAOYSA-N 0.000 description 1
- CPBZARXQRZTYGI-UHFFFAOYSA-N 3-cyclopentylpropylcyclohexane Chemical compound C1CCCCC1CCCC1CCCC1 CPBZARXQRZTYGI-UHFFFAOYSA-N 0.000 description 1
- OKISUZLXOYGIFP-UHFFFAOYSA-N 4,4'-Dichlorobenzophenone Chemical compound C1=CC(Cl)=CC=C1C(=O)C1=CC=C(Cl)C=C1 OKISUZLXOYGIFP-UHFFFAOYSA-N 0.000 description 1
- GPGLSSKLPVRDCD-UHFFFAOYSA-N 4-(2-bromoethyl)-1,2-diethylbenzene Chemical compound CCC1=CC=C(CCBr)C=C1CC GPGLSSKLPVRDCD-UHFFFAOYSA-N 0.000 description 1
- XRTBTCYGKTYNEC-UHFFFAOYSA-N 4-(2-bromoethyl)-2-methyl-1-pentylbenzene Chemical compound CCCCCC1=CC=C(CCBr)C=C1C XRTBTCYGKTYNEC-UHFFFAOYSA-N 0.000 description 1
- TWDUMXUCXGJUCT-UHFFFAOYSA-N 4-[2-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC=C1C1=CCNCC1 TWDUMXUCXGJUCT-UHFFFAOYSA-N 0.000 description 1
- RFJBFMQLLHGBFH-UHFFFAOYSA-N 4-[2-(trifluoromethyl)phenyl]piperidin-4-ol Chemical compound C=1C=CC=C(C(F)(F)F)C=1C1(O)CCNCC1 RFJBFMQLLHGBFH-UHFFFAOYSA-N 0.000 description 1
- RJFISGALWPADNA-UHFFFAOYSA-N 4-[3-(trifluoromethyl)phenyl]-1,2,3,6-tetrahydropyridine;hydrochloride Chemical compound Cl.FC(F)(F)C1=CC=CC(C=2CCNCC=2)=C1 RJFISGALWPADNA-UHFFFAOYSA-N 0.000 description 1
- FPWNLURCHDRMHC-UHFFFAOYSA-N 4-chlorobiphenyl Chemical group C1=CC(Cl)=CC=C1C1=CC=CC=C1 FPWNLURCHDRMHC-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- KNAHARQHSZJURB-UHFFFAOYSA-N 6-propyl-2-thio-Uracil Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229940022663 Acetate Drugs 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N Aluminium hydride Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229940040526 Anhydrous Sodium Acetate Drugs 0.000 description 1
- 229940064004 Antiseptic throat preparations Drugs 0.000 description 1
- 210000000709 Aorta Anatomy 0.000 description 1
- 210000000702 Aorta, Abdominal Anatomy 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 229940072107 Ascorbate Drugs 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- RWCCWEUUXYIKHB-UHFFFAOYSA-N Benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 240000000218 Cannabis sativa Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- 229920001429 Chelating resin Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- 210000000805 Cytoplasm Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N Diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000272184 Falconiformes Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940093915 Gynecological Organic acids Drugs 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 210000004698 Lymphocytes Anatomy 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010053643 Neurodegenerative disease Diseases 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- NHKJPPKXDNZFBJ-UHFFFAOYSA-N Phenyllithium Chemical compound [Li]C1=CC=CC=C1 NHKJPPKXDNZFBJ-UHFFFAOYSA-N 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N Phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000004623 Platelet-Rich Plasma Anatomy 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N Propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229940076788 Pyruvate Drugs 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- OKIZCWYLBDKLSU-UHFFFAOYSA-M Tetramethylammonium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 1
- GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
- DBGVGMSCBYYSLD-UHFFFAOYSA-N Tributyltin hydride Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- WOAORAPRPVIATR-UHFFFAOYSA-N [3-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(C(F)(F)F)=C1 WOAORAPRPVIATR-UHFFFAOYSA-N 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 230000002378 acidificating Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002421 anti-septic Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-M benzoate Chemical compound [O-]C(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-M 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- POOXOHISLGOAEF-UHFFFAOYSA-N bis[3-(trifluoromethyl)phenyl]methanone Chemical compound FC(F)(F)C1=CC=CC(C(=O)C=2C=C(C=CC=2)C(F)(F)F)=C1 POOXOHISLGOAEF-UHFFFAOYSA-N 0.000 description 1
- 229910000085 borane Inorganic materials 0.000 description 1
- 229910000090 borane Inorganic materials 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- OCKPCBLVNKHBMX-UHFFFAOYSA-N butylbenzene Chemical compound CCCCC1=CC=CC=C1 OCKPCBLVNKHBMX-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- HHNHBFLGXIUXCM-GFCCVEGCSA-N cyclohexylbenzene Chemical compound [CH]1CCCC[C@@H]1C1=CC=CC=C1 HHNHBFLGXIUXCM-GFCCVEGCSA-N 0.000 description 1
- XDRVAZAFNWDVOE-UHFFFAOYSA-N cyclohexylboronic acid Chemical compound OB(O)C1CCCCC1 XDRVAZAFNWDVOE-UHFFFAOYSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 230000001086 cytosolic Effects 0.000 description 1
- 230000003111 delayed Effects 0.000 description 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 1
- DMJZZSLVPSMWCS-UHFFFAOYSA-N diborane Chemical compound B1[H]B[H]1 DMJZZSLVPSMWCS-UHFFFAOYSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- PYHXGXCGESYPCW-UHFFFAOYSA-N diphenylacetic acid Chemical compound C=1C=CC=CC=1C(C(=O)O)C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 230000013080 embryo development ending in birth or egg hatching Effects 0.000 description 1
- 230000013144 embryo development ending in seed dormancy Effects 0.000 description 1
- 230000001605 fetal Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N fumaric acid Chemical compound OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 235000012765 hemp Nutrition 0.000 description 1
- 230000002440 hepatic Effects 0.000 description 1
- KLGZELKXQMTEMM-UHFFFAOYSA-N hydride Chemical compound [H-] KLGZELKXQMTEMM-UHFFFAOYSA-N 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000302 ischemic Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-M isethionate Chemical compound OCCS([O-])(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-M 0.000 description 1
- KXUHSQYYJYAXGZ-UHFFFAOYSA-N isobutylbenzene Chemical compound CC(C)CC1=CC=CC=C1 KXUHSQYYJYAXGZ-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 1
- OCZDCIYGECBNKL-UHFFFAOYSA-N lithium;alumanuide Chemical compound [Li+].[AlH4-] OCZDCIYGECBNKL-UHFFFAOYSA-N 0.000 description 1
- 230000002934 lysing Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 235000012766 marijuana Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940039748 oxalate Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L propanedioate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridine hydrochloride Substances [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 230000001105 regulatory Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000001187 sodium carbonate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 101700082413 tant Proteins 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- YTZKOQUCBOVLHL-UHFFFAOYSA-N tert-butylbenzene Chemical compound CC(C)(C)C1=CC=CC=C1 YTZKOQUCBOVLHL-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- UORVGPXVDQYIDP-UHFFFAOYSA-N trihydridoboron Substances B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N α-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
Abstract
The invention concerns a compound of formula (I) for preparing pharmaceutical compositions designed to increase the proportions of circulating, cellular and extracellular TGF-&bgr;1.
Description
USE OF TETRAHYDROPYRIDINES 4-YOUR BSTITUIDES TO MAKE MEDICINES THAT ACT ON TGF-B1
DESCRIPTION OF THE INVENTION
The present invention relates to the use of certain derivatives of
1, 2,3,6-tetrahydropyridine, and its pharmaceutically acceptable salts and solvates for the preparation of medicaments capable of increasing the levels of TGF-β1 (transforming growth factor-β1). TGF-β1 is a ubiquitous and multifunctional peptide, which is constituted, in its formative, by two identical subunits linked by a disulfide bridge. As illustrated by P.
Bedesse and V. Paradis (Journal of Hepatology, 1995, 22, 37-42), TGF-β1 has been identified as a factor that induces cell growth of transformed fibroblasts, but many other cell functions have been successfully discovered. The application WO 93/09808 describes the use of TGF-β1 for the treatment of damage to the central nervous system. The applications WO 96/34881 and WO 94/17099 claim novel peptides, which have an activity similar to that of TGF-β1, and which can be used for the treatment of several pathologies. TGF-β1 for example is involved in the control of the cell cycle, in angiogenesis, in cell differentiation, in embryogenesis, in tissue repair, as well as in apoptosis. Among these activities, the anti-apoptotic effect of TGF-β1 is very important due to its pharmacological implications. "Apoptosis" or "programmed cell death" indicates all the physiological processes linked to cell death. In its terminal phase, apoptosis is characterized by an activity of endonucleases, which unfold DNA double chain structure in the internucleosomal regions, thus generating mono- and oligo-nucleosomes, which form complex with histones. An enrichment in oligo- and mono-nucleosomes linked to histones is thus observed in the cytoplasm of apoptotic cells. Although this phenomenon is physiological, in contrast to necrosis, it can also be caused by pathological stimulation. D. A. Carson and J. M. Ribeiro reports, (The Lancet 1993, 341, 1251-1254), the role of apoptosis in certain pathologies such as immuno-depression, immune deficiencies in patients presenting with AIDS, cell aging, and degenerative disease. J. Mathieu et al. (Ann. Pharmaceutiques francaises 1996, 54,
, 193-201) demonstrated that the pathological effects caused by chemical and physical agents such as free radicals and ionization radiation are caused by the pro-apoptotic effects of these agents. The products of apoptosis regulation were described in the patent application WO 96/21449. The general formula includes tant inhibitors as stimulators of apoptosis. without giving the meaning of distinction between one and the other. It has now been found that certain tetrahydropyridines increase the circulation and cellular and extracellular levels of TGF-β1. In this way, the object of the present invention is the use of 4, 4-substituted 1, 2,3,6-tetrahydropyridine of the formula (I):
wherein: -Ri represents a halogen or a CF3, an alkyl group of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms; -And represents a nitrogen atom or a CH group; -Z 'and Z "ccaaddaa uunnoo rreepprreesseennttaann hhiiddrróóggeennoo oo uunn ggrruuppoo aallqquuiilloo of 11 to 3 carbon atoms, or one represents hydrogen and the other represents a hydroxy group, or both, together, represent an oxo group;
-Z represents * a phenyl radical; * monosubstituted or with a substituent X, X being: a) an alkyl group of 1 to 6 carbon atoms; alkoxy of 1 to 6 carbon atoms; carboxyalkyl of 3 to 7 carbon atoms; alkoxycarbonyl of 1 to 4 carbon atoms-alkyl of 1 to 6 carbon atoms; carboxyalkoxy of 3 to 7 carbon atoms or alkoxy carbonyl of 1 to 4 carbon atoms-alkoxy of 1 to 6 carbon atoms; b) a group selected from the group of cycloalkyl of 3 to 7 carbon atoms, cycloalkyloxy of 3 to 7 carbon atoms, cycloalkylmethyl of 3 to 7 carbon atoms, cycloalkylamino of 3 to 7 carbon atoms and cyclohexenyl, it being possible for said group is substituted with a halogen, hydroxy, alkoxy of 1 to 4 carbon atoms, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms, amino, mono or dialkylamino of 1 to 4 carbon atoms; c) a group selected from phenyl, and phenoxy, phenylamino, n-alkylphenylamino of 1 to 3 carbon atoms, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl or styryl, it being possible for said group to be mono- or poly-substituted in the phenyl group with a halogen, CF3, alkyl of
1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, cyano, amino, mono or dialkylamino of 1 to 4 carbon atoms, acylamino of 1 to 4 carbon atoms, carboxy, alkoxycarbonyl of 1 to 4 carbon atoms , aminocarbonyl, mono or dialkylamino of 1 to 4 carbon atoms, aminoalkyl of 1 to 4 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms or haloalkyl of 1 to 4 carbon atoms; A disubstituted phenyl radical with a substituent R2, R2 being a halogen or a hydroxy group, methyl, ethyl, alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 4 carbon atoms, or trifluoromethyl, and with a substituent X, X being defined as above: * a 1-naphthyl or 2-naphthyl radical; * a 1-naphthyl or 2-naphthyl radical substituted at positions 5, 6, 7 and / or 8 with 1 or 2 hydroxyl groups, one or two alkoxy groups of 1 to 4 carbon atoms or a 6,7-methylenedioxy group; -o Z "is hydrogen and Z and Z 'represent, each independently, an unsubstituted or mono, di or trisubstituted phenyl group, or one of its pharmaceutically acceptable salts or solvates, for the preparation of pharmaceutical compositions capable of increasing the circulation and cellular and extracellular levels of TGF-β1 According to an advantageous aspect, the object of the invention is the use of a compound of the formula (I), wherein Y is CH and R is o- or m- CF3 According to a preferred aspect, Y is CH, R ^ is o- or m-CF3 and Z 'and Z "are hydrogen. According to another preferred aspect, Y is CH, R ^ is o- or m-CF, Z 'and Z "represent an oxo group and Z is 4-diphenol, In accordance with a further advantageous aspect, the object of The invention is to use the compound of the formula (I), wherein Y is CH, RT is o- or m-CF3, Z 'and Z "are hydrogens, and Z represents a monosubstituted phenyl radical with a substituent X, X being a), b), c) or one of its pharmaceutically acceptable salts or solvates.
According to another preferred aspect, the invention relates to the use of the compound of the formula (1) wherein Y is CH, R2 is o- or / 77-CF3, Z 'and Z "are hydrogen and Z represents either phenyl or monosubstituted radical with a group X ', X' being an unsubstituted phenyl
0 substituted with 1 to 3 halogens, 1 to 3 CF3, 1 to 3 alkyls of 1 to 4 carbon atoms, 1 to 3 alkoxies of 1 to 4 carbon atoms, 1 to 3 cyans, 1 to 3 aminos, 1 to 3 mono or diakylaminos of 1 to 4 carbon atoms, 1 to 3 acylaminos of 1 to 4 carbon atoms, 1 to 3 carboxys, 1 to 3 alkoxycarbonyls of 1 to 4 carbon atoms, 1 to 3 aminocarbonyls, 1 to 3 mono or di-alkylaminocarbonyl of 1 to 4 carbon atoms, 1 to 3 aminoalkyl of 1 to 4 carbon atoms,
1 to 3 hydroxyalkyl of 1 to 4 carbon atoms or 1 to 3 haloalkyl of 1 to 4 carbon atoms; or a phenyl radical disubstituted with a substituent R2, 2 being a halogen or a hydroxy group, methyl, ethyl, alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 4 carbon atoms or trifluoromethyl, or with a substituent X ', X 'being as defined above, or one of its pharmaceutically acceptable salts or solvates. According to another preferred aspect, the invention relates to the use of the compound of the formula (I), wherein X is CH, R, is o- or / 77-CF3, Z 'and Z "are hydrogen and Z is a phenyl group substituted at positions 3 and 4 with an alkyl group of 1 to 6 carbon atoms, or a pharmaceutically acceptable salt or solvate thereof According to another preferred aspect, the invention relates to the use of the compound of the formula I), where Y is CH, R ^ is o- or m-CF3, Z "is hydrogen and Z and Z ', identical, each represents a phenyl group; a phenyl group substituted in the 2, 3 or 4 position with a fluorine or chlorine atom or with a methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl group , trifluoromethyl, cyano, methoxy, methylthio, methylsulfonyl, ethoxy, ethylthio, ethylsulfonyl, alkoxycarbonyl of 1 to 3 carbon atoms or dialkylaminocarbonium of 1 to 3 carbon atoms; a phenyl group disubstituted at positions 2, 4; 3. 4; 3, 5 or 2, 6 with a chlorine or fluorine atom, or with a methyl, ethyl, trifluoromethyl, cyano or methoxy group; or a triphenyl group disubstituted at positions 2, 4, 5; 2, 4, 5 or 2, 4, 6 with a chlorine or fluorine atom, or with a methyl, ethyl, trifluoromethyl, cyano or methoxy group, or one of its pharmaceutically acceptable salts and solvates.
According to a particularly preferred aspect, the invention relates to the use of a compound of the formula (I), wherein Y is CH, Ri is m-trifluoromethyl, Z 'and Z "are hydrogen and Z represents a naphthyl group, 6,7-dimethoxy-2-naphthyl or 6,7-methylenedioxy-2-naphthyl, or one of its pharmaceutically acceptable salts and solvates A particularly advantageous compound according to the present invention can be selected from: -1- ( 2-naphth-2-ylethyl) -4- (3-trif luoromethylphenyl) -1, 2,3,6-tetrahydropyridine; -1- [2- (6,7-dimethoxynaphth-2-yl) ethyl] -4- ( 3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine; -1- [2- (6,7-methylenedioinaphth-2-yl) et il] -4- (3-trif luoromethylphenyl) -1,2, 3,6-tetrahydropyridine; -1- [2- (4-isobutylf in yl) propyl] -4- (3-trif luoromethyl) in i I) -1,2,3,6-tetrahydropyridine; - 1 - [(2S ) -2- (4-isobutylphenyl) propi I] -4- (3-trif luoromethyl) in i I) - 1, 2,3,6-tetrahydropyridine; -1 - [(2R) -2- (4-isobutyl fe ni I) propyl] -4- (3-trif Ioromethyl nil) -1, 2,3,6-tetr ahydropyridine; 1- [2- (4-isobutyl-l-phenyl) -ethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine; - 1- [2- (4-terbu ti If in il) ethyl] -4- (3-trif-1-uoro-methylf-enyl) -1,2,3,6-tetrahydropyridine; 1- [2- (4-isobutyl-phenyl) -2-methyl-1-propyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4-or propylphenyl) ethyl] -4- (3-trifluoromethyl) in I) -1,2,3,6-tetrahydropyridine; -1- [2- (3'-chloro-4-bif on i I I Jet il] -4- (3-trif luoromethyl-phenyl) -1,3,6,6-tetrahydropyridine; (2'-cl or ro-4-bifenyl il) ethyl] -4- (3-trif luoromet ilf enyl) -1,2,3,6-tetrahydropyridine; -1-t2- (4'-chloro-4 -biphenylyl) ethyl] -4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine; -1- [2- (4'-f I uoro-4-bif in i I) ethyl] -4- (3-trifluoromethylphenyl) -1,3,6,6-tetrahydropyridine;
- 1- [2- (3'-trifluoro-methyl-4-bifen i I) ethyl] -4- (3-trifluoromethyl) in 1) -1, 2,3,6-tetrahydropyridine; -1- [2- (4-cyclohexylphenyl) ethyl] -4- (3-trif luoromethyl) in yl) -1,2,3,6-tetrahydropyridine; -1- [2- (4-biphenyl) -2-ethyl] -4- (4-fluorophenyl) -1, 2, 3, 6 -tet rahidropi ridine;
- 1- [2- (4-bifenyl) -2meti I pro pil] -4- (3-trif luoromethylphenyl) -1,2, 2,3,6-tetrahydropyridine; -1- [2- (4-phenoxypynyl) -2-ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4-benzyl) eni I) -2-e t i I] -4- (3-t rif luoromethyl) in i I) -1,2, 3,6-tetrahydropyridine; -1- [2- (4-n-butylphenyl) ethyl] -4- (3-trif luoromethylphenyl) -1,2, 2,3,6-tetrahydropyridine; -1- [2- (4-biphenylyl) ethyl] -4- (3-trif luoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4-n-butoxyphenyl) etiI] -4- (3-t rif luoromethylphenyl) -1,2, 2,3,6-tetrahydropyridine; -1-I2- (3,4-diethylphenyl) ethyl] -4- (3-t rif luoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2 - (3-methyl-4-pentylethyl) ethyl] -4- (3-trifluoromethyl-phenyl) -1,2,6,6-tetrahydropyridine; -1- [2- (4-methyl-3-pentylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (3,4-diethylphene) ethyl] -4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine;
- 1- [2- (2,2-diphenylethyl] -4- (3-t rif luoromethyl) in i I) -1, 2,3,6-tetrahydropyridine; -1- [2, 2- (4, 4 ' -dichlorodif en il) ethyl] -4- (3-trif luoromethyl) en il) -1, 2,3,6-tetrahydropyridine; -1- [2, 2- (3,3'-bistrifluoromethyldifeni) ethyl] - 4- (3-t rif luoromethylphenyl) -1,2,3,6-tetrahydro pyridine; -1- [2,2- (4,4'-dimethoxydiphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1 , 2,3,6-tetrahydropyridine; -1- [2- (4-f luorofenyl) -2-f in ileyl] -4- (3-trif luoromethyl) eni I) - 1,2,3,6-tetrahydropyridine; -1- (3, 3-di-fe-nyl-propyl) -4- (3-t-fluoro-methyl-n-nyl) -1,2,3,6-tetrahydropyridine; -1- [2,2- (4,4; -dichlorodiphenyl) ethyl] -4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine; -1- [2- (3'-chloro bife nyl-4-yl) -2-oxoethyl ] -4- (3-tri-fluoro-met-phenyl) -1, 2,3,6-tetrahydropyridine; -1- [2- (2'-clo-robif-enyl-4-yl) -2-oxoetiI] -4- ( 3-trif luoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4'-chlorobi-phenyl-4-yl) -2-oxoethyl] -4- (3-trichloro-methyl-fe nil) -1, 2,3,6-tetrahydropyridine; -1- [2- (4-isobutylphenyl ) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine; -1- [2- (4-benzyl-faith-nyl) -2-oxo-ethyl] -4- (3-t-rifyl-uoro-methyl-phenyl) -1, 2,3,6-tetrahydropyridine; -1 - [2 - (4-cyclohexyl nyl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4'-f I uoro bif en il-4-yl) -2-oxoethyl] -4- (3-trif luoromethyl) en i l) -1, 2,3,6-tetrahydropyridine; -1- [2- (4-7-Butylf-enyl) -2-oxoethyl] -4- (3-trifluoromethyl) in i I) -1,2,3,6-tetrahydropyridine; -1- [2- (biphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4-Butylphenyl) -2-oxoethyl] -4- (3-trifluoromethylf eni I) -1,2,3,6-tetrahydropyridine; -1- [2- (4'-trifluorooxy methyl bife nii-4-yl) -2-oxoethyl] -4- (3-trif luoromethyl) en yl) -1,2, 2,3,6-tetrahydropyridine; -1- [2- (2, 3'-Dichloro-4-biphenylyl) ethyl] -4- (3-tri-fluoro-methyl-phenyl) -1, 2,3,6-tetrahydropyridine; -1- [2- (3-Chloro-4-biphenylyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (3 ', 5, -dichloro-4-biphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine: -1- [2- (2 , 4, -dichloro-4-biphenylyl) ethyl] -4- (3-trif luoromethyl-enyl) -1,2, 2,3,6-tetrahydropyridine: - 1- [2- (2-chloro-4-bif in ili l) ethyl] -4- (3-t rif luoromethylphenyl) -1,2,3,6-tetrahydropyridine: -1- [2- (3'-chloro-4-b-phenyl) ethyl] -4- ( 3-trifluoromethiifenii) -1,2,3,6-tetrahydropyridine. -1-. { 2- (2-Fluoro-4-biphenylyl) ethyl] -4- (3-trif luoromethylphenyl) -1, 2,3,6-tetrahydropyridine.
-1- [2- (4-methoxy-3-bi-phenyl-nilyl) -ethyl] -4- (3-trifluoro-methyl-phe nyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4'-methoxy-4-biphenylyl) ethyl] -4- (3-t rif luoromethyl) in I) -1,2,3,6-tetrahydropyridine; -1- [2- (4'-hydroxy-4-bif in ili I) e t i I] -4- (3-1 rif luoromethyl) in i I) -1,2, 3,6-tetrahydropyridine; -1- [2- (4'-ethoxycarbonylbutoxy-4-byl nyl) ethyl] -4- (3-trifluoromethyl) n-1) -1,2,3,6-tetrahydropyridine; -1 - [2- (3-biphenylyl) ethyl] -4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydro-pyridine; -1- [2- (3'-Chloro-4'-fluoro-4-biphenylyl) ethyl] -4- (3-trifluoromethylphenyl) -1, 2,
3, 6-tetrahydro pyridine; -1- [2- (2, -trifluoromethyl-4-bif enyl) ethyl] -4- (3-trif luoromethylphenyl) -1,2,3,6-tetrahydropyridine; -1 - [2- (bifenyl-4-yl) ethyl] -4- (2-trif luoromethylphenyl) -1,2,3,6-tetrahydro-pyridine; -1- [2- (4-cyclohexenyl-phenyl-n-ethyl) -4- (3-trifluoromethyl-phenyl) -1,3,3,6-tetrahydropyridine; -1- [2- (3,4-diisobutylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine; - 1 - [2 - (3, 4-d i propi If in il) ethyl] -4- (3-trif I uoro methylphenyl) -1,2,3,6-tetrahydropyridine; -1- [2- (4-cyclohexylphenyl) etii] -4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine: -1- [2- (4-isobutylphenyl) ethyl] - 4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine; -1- [2- (2'-trifluoromethyl-phenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3-tetrahydropyridine; -1- [2- (3'-trif Ioromethyl bif in yl-4-yl) -2-oxoethyl] -4- (3-trif luoromethylphenyl) -1,2,3,6-tetrahydropyridine; and its pharmaceutically acceptable salts and solvates. 1- (2-naphth-2-ylethyl) -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine known by its laboratory code, SR 57746 and its pharmaceutically acceptable salts and solvates, especially its hydrochloride (SR 57746A), are particularly preferred compounds for use in accordance with the present invention. Certain compounds of the formula (I) are novel products.
Thus, according to other aspects thereof, the present invention relates to a compound of the formula (I) selected from: 1- [2- (6,7-methylenedioxinaphth-2-yl) ethyl] -4 - (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine, 1 - [2- (4-cyclohexe nil fe ni I) eti l] -4- (3-trifluoromethyl nil) -1, 2,3 , 6-tetrahydropyridine, and 1- [2- (biphenii-4-yl) ethyl] -4- (3-trifluoromethylphenol) -1,2,3,6-tetrahydropyridine, and their pharmaceutically acceptable salts and solvates. Salts with pharmaceutically acceptable bases are, for example, those with alkaline or alkaline earth metals, such as sodium, potassium, calcium, magnesium and those with organic bases, such as amines, basic amino acids (lysine, arginine, histidine), trometamol, N -metüglutamine, etc. Salts with pharmaceutically acceptable acids are, for example, those with mineral acids, such as hydrochloride, hydrobromide, borate, phosphate, sulfate, acid sulfate, acid phosphate, and those with organic acids, such as citrate, benzoate, ascorbate, methyl sulfate, naphthalene-2-sulfonate, picrate, fumarate, maleate, malonate, oxalate, succinate, acetate, tartrate, mesylate, tosylate, isethionate, a-ketoglutarate, cc-glycerophosphate, glucose-1-phosphate, etc. The compounds of the formula (I), wherein Z 'and Z "are hydrogen or an alkyl group having from 1 to 3 carbon atoms are prepared as described in WO 97/01536. The compounds of the formula (I), in where one of Z 'and Z "is hydrogen and the other is a hydroxyl, as well as the compounds wherein Z' and Z" together represent an oxo group, can be prepared as described in WO 93/11107. Formula (I), wherein Z "is hydrogen and Z 'and Z each independently represents an unsubstituted, mono, di or tri-substituted group or phenyl are prepared according to the following method: (a) an aryl- , 2, 3,6-tetrahydropyridine of the formula (II):
wherein Y R, as defined above, is allowed to react with an acid of the formula (III):
HO - C - CH (lll) \ Z '
wherein Z and Z 'are as defined above, or with one of their functional derivatives, (b) the carbonyl intermediate of the formula (IV):
is reduced, and (c) the compound of the formula (I) is isolated and, optionally, transformed to one of its salts or solvates. The reaction step (a) can conveniently be carried out in an organic solvent at a temperature between -10 ° C and the reflux temperature of the reaction mixture; preferably the reaction is carried out at low temperature. The reaction solvent used is preferably a halogenated solvent such as methylene chloride, dichloroethane, 1,1,1-trichloroethane, chloroform and the like, and an alcohol such as methanol or ethanol, but other organic solvents can also be employed which are compatible with the reagents employed, for example, dioxane, tetrahydrofuran or a hydrocarbon such as hexane. The reaction may conveniently be carried out in the presence of a proton acceptor, for example, an alkaline carbonate or a tertiary amine. The pound acid, optionally activated (with BOP, for example), the anhydride, a mixed anhydride, an activated ester or an acid halide, preferably chloride or bromide, can be used as a suitable functional derivative of the acid of the formula (III) . Among the activated esters, the p-nitrophenyl ester is particularly preferred, but the methoxyphenyl, trityl, benzhydryl esters and the like are also suitable. The reduction of step (b) may conveniently be carried out by suitably reducing agents such as aluminum hydrides or a lithium-aluminum complex hydride in an inert organic solvent at a temperature between 0 ° C and the reflux temperature of the mixture. of reaction according to usual techniques. "Inert organic solvent" is understood to be a solvent that does not interfere with the reaction. Such solvents are, for example, ethers, such as diethyl ether, tetrahydrofuran, dioxane or 1,2-dimethoxyethane. The compound of the formula (I) obtained is isolated according to usual techniques and optionally transformed to one of its addition acid salts or, when an acidic group is present, the amphoteric character of the compound allows the separation of the salts either with acids or bases. The starting amines of the formula (II), wherein Y is CH, are known compounds or can be prepared according to procedures analogous to those used to prepare the known compounds. The starting amines of the formula (II), wherein Y is N, can be prepared through the reaction of a suitable 2-halopyridine of the formula (p):
wherein R-i is as defined above, and Hal is a halogen atom, with a 1, 2, 3,6-tetrahydropyridine of the formula (q):
wherein p represents a protecting group such as a benzyl group, and Z represents a substituent that allows nucleophilic substitution of the halogen of pyridine. Such substituents are, for example, trialkylstannanes, such as tributylstannane, or Grignard compounds. The 1,2,3,6-tetrahydropyridine is then deprotected by cleaving the protecting group under suitable conditions. The acids of the formula (III) can be prepared according to the Wittig reaction through the reaction of a suitable benzophenone of the formula (r):
/ O (r) \ Z *
wherein Z and Z 'are as defined above, with trimethylsulfoxonium iodide / BF3-Et2O and oxidation of the intermediate aldehyde of the formula (w):
-CHO (w) Z '
according to the method described in J. Am. Chem. Soc, 1990. 112 (18): 6690-6695, to obtain the corresponding acid. According to another method, the compounds of the formula (I), wherein Z "is hydrogen can also be prepared through the reaction of an aryl-1, 2,3,6-tetrahydropyridine of the formula (II):
wherein R-i and Y are as defined above, with an aldehyde of formula (w) above in the presence of a reducing agent such as sodium cyanoborohydride, according to known techniques. The compounds of the formula (I), wherein R, is m-trifluoromethyl, Y is CH, Z 'and Z "are hydrogen and Z is a naphthyl group substituted with one or more alkoxy groups with a methylenedioxy group, are prepared as described in EP 0 458 697. 1 - (2 -naft-2-ylethyl) -4- (3-t rif luoromethyl) in il) -1, 2,3,6-tetrahydropyridine and its pharmaceutically acceptable salts and solvates, especially the hydrochloride, can be prepared in accordance with EP 0 101 381. An advantageous method provides the reaction of 2- (2-bromoethyl) naphthalene and 4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine and the isolation preferably of 1- (2-naphth-2-hydrochloride -ethyl) -4- (3-trif luoromethylphenyl) - 1,2,3,6-tetrahydropyridine
(SR 57746A), which is then crystallized in an ethanol / water mixture by heating and cooling to 5 ° C with a cooling gradient of 10 ° C / hour and a stirring speed of 400 rpm, in order to obtain a mixture of the two crystalline forms in a ratio of approximately 66/34. The 1- (2-naphth-2-ylethyl) -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride is preferably used in a microparticulate form, for example, in an essentially amorphous form obtained through atomization, or in a microcrystalline form obtained through micronization. The effect of the compounds of the formula (I) on the increase of the levels of TGF-β1 was evaluated with the help of tests on lyse muscle cells, as well as on levels in the blood and rat diaphragms after administration in the representative compounds of the invention. Both latent TGF-β1 and active TGF-β1 were determined in lyse muscle cells through incubation with hydrochloric acid. In these tests, representative examples of formula (I) showed an elevation in TGF-β1 levels. The anti-apoptotic activity was measured in the same cells vis-a-vis, the pro-apoptotic activity of a lack in the serum and after the addition of toxic compounds such as vincristine or growth factors such as nerve growth factor (NGF) with the help of a specific ELISA determination kit (assay with enzyme-linked immunosorbent), which detects the presence of oligonucleosomes, the presence of which within the cells is a specific marker of programmed cell death (apoptosis ), according to the method described by Del
Bino G. et al., (Experimental Cell Research, 193, 27, 1991 and 195,
485, 1991) or Darzynkiewicz A. and others, (Cytometry, 13, 795, 1992). In all three cases, the representative compounds of the invention, especially: -1- [2- (3,4-diethylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine ( compound A); -1- [2- (biphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine (compound B); -1- [2- (biphenyl-4-yl) etl] -4- (3-trifluoromethylphenii) -1, 2,3,6-tetrahydropyridine (Compound C); -1- [2- (6,7-Methylenedioxinaphth-2-ethyl] -4- (3-tri fluoro methyl nyl) -1, 2,3,6-tetrahydropyridine (compound D); -1- [ 2- (4-cyclo-free en-yl) etii] -4- (3-trif luoromethyl-enyl) -1,2,3,6-tetrahydropyridine (compound E); -1- [2- (biphenyl-4 -yl) ethyl] -4- (3-trif luoromethylf eni I) -1, 2,3,6-tetrahydropyridine (compound F), and -1- (2-naphth-2-ylethyl) -4- ( 3-trif luoromethylf eni I) -1, 2,3,6-tetrahydropyridine (SR 57746) and its pharmaceutically acceptable salts, inhibits, as a function of time and dose, the pro-apoptotic effect induced by the lack of the serum or even by the addition of NGF or vincristine Thus, according to a further aspect, the present invention relates to the use of tetrahydropyridines of the formula (I), the advantageous and preferred compounds mentioned above, or their salts and pharmaceutically acceptable solvates for the preparation of a medicament for treating diseases that can be treated by increasing the levels of TGF-.beta.1. pathologies are, for example, diseases related to an abnormal apoptotic activity, ocular diseases such as cataracts or glaucoma, osteoporosis, bone fracture, epidermal lesions, restenosis, conditions related to a proliferation or incorrect migration of hepatic muscle cells, inflammations of the respiratory system, asbestosis, silicosis, lupus erythematosus, Goodpasture's syndrome, granulomatosis, eosinophilic granulomatosis, gastric and duodenal ulcers, oseofagitis, enteritis, gastritis, septicemia, malfunction of hematopoiesis and / or lymphopoiesis, cystic fibrosis. According to a particularly advantageous aspect, the present invention relates to the use of tetrahydropyridines of the formula (I), advantageous and preferred compounds mentioned above, or their pharmaceutically acceptable salts or solvates for the preparation of medicaments capable of inhibiting apoptosis.
By virtue of this anti-apoptotic activity, the compounds of the present invention can be used for the preparation of medicaments for treating cancer and their metastases, infections by antivirus such as HIV and HITV 1 and 2 (human immunodeficiency virus and lymphocyte virus). T human) and the consequences thereof such as ATL (adult cell leukemia), leukemia, myelopathies and arthropathies, hepatitis (C, A, B, F), AIDS, immune deficiencies, cell aging, tissue degeneration phenomenon , inflammation, cell proliferation, infectious diseases, graft rejection, acute or chronic rheumatoid arthritis, ulcerative colitis, thrombocytopenic purpura, autoimmune erythromoclast anemia, juvenile diabetes (Type I) (insulin dependent), myelodysplastic syndrome, Huntington's disease, prion diseases, ARDS, prostatic hypertrophy, asthma, atherosclerosis and its thrombo-embolic complications, kidney diseases, glomerolunephritis, ischemic pathologies such as myocardial infarction, myocardial ischemia, coronary vasospasm, angina and heart failure, chronic pancreatitis, autoimmune gastritis, primary biliary cirrhosis. According to an advantageous aspect, the present invention relates to the use of tetrahydropyridines of the formula (I), to one of the aforementioned advantageous or preferred compounds, or their pharmaceutically acceptable salts or soivates for the preparation of medicaments capable of treating a disease such as graft rejection or acute or chronic rheumatoid arthritis. In accordance with the object of the present invention, "treatment of diseases" is understood to mean both treatment and prevention of diseases, when possible. In this way, for example, when graft rejection is considered, the pharmaceutical compositions can be used in the concept of prevention. According to one more aspect. The invention relates to a method for increasing the circulation and cellular and extracellular levels of TGF-β1. According to another of its aspects, the present invention relates to a method for inhibiting apoptosis, which comprises administration to a mammal with the administration thereof of an effective dose of a compound of the formula (I), from one of the advantageous or preferred compounds mentioned above, or their pharmaceutically acceptable salts and solvates, advantageously SR 57746, or one of their pharmaceutically acceptable salts and solvates. According to a preferred aspect, SR 57746 and its pharmaceutically acceptable salts and solvates are administered in a microparticle form, preferably in a microparticulate form of the hydrochloride. The compounds of the formula (I), one of the advantageous or preferred compounds mentioned above or their pharmaceutically acceptable salts and solvates, are preferably administered orally. The amount of the active substance that will be administered depends on the degree of advancement of the disease, as well as the age and weight of the patient. However, unit doses generally comprise from 0.25 to 700 mg, advantageously from 0.5 to 300 mg, and most preferably from 1 to 150 mg, for example, "between 2 and 50 mg of the active principle." These unit doses are usually administered once or more times a day, preferably 1 to 3 times a day, the total dose in humans ranges from 0.5 to 1400 mg per day, for example from 1 to 900 mg per day, advantageously from 2 to 500 mg per day, and very conveniently 2 to 200 mg per day When the active principle administered is, for example, SR 57746, the unit dose generally comprises 0.5 to 10 mg, advantageously from 1 to 5, and preferably from 1 to 3. mg, for example, 1-1.5-2-2.5-3 mg of the active principle These unit doses are usually administered once or more times a day, preferably 1 to 3 times a day, the total dose in humans varies of 0.5 and 50 mg per day, for example from 1 to 20 mg per day, advantageously from 2 to 10 mg per day. The above doses and amounts refer to the compounds of the formula (I) or to one of the advantageous or preferred compounds mentioned above, in an unsalted form. In the pharmaceutical compositions of the present invention for oral administration, the active ingredient can be administered as unit forms for administration, in a mixture with classical pharmaceutical carriers, to mammals, to animals and to humans for the treatment of the aforementioned diseases. Suitable unit forms of administration comprise, for example, tablets, which are optionally labeled, gelatin capsules, powders, granules and oral solutions or suspensions. When preparing a solid composition in the form of tablets, the main active ingredient is mixed with a pharmaceutical carrier such as gelatin, starch, lactose, magnesium stearate, talcum, gum arabic or analogs thereof. The tablets may be coated with sucrose or other suitable materials or may still be treated so as to have a sustained or delayed activity and to continuously release a predetermined amount of the active ingredient. A gelatin capsule preparation is obtained by mixing the active ingredient with a diluent and emptying the obtained mixture into soft or hard gelatin capsules. A preparation in the form of a syrup or elixir may contain the active ingredient together with a sweetener, preferably an acalorific sweetener, methylparaben and propylparaben as antiseptics, as well as a flavoring agent and a suitable coloring agent. The powders or granules that can be dispersed in water can contain the active ingredient in a mixture with dispersing agents or wetting agents, or suspending agents, such as polyvinylpyrrolidone, as well as sweeteners or flavor correctors. The active ingredient can also be formulated in the form of microcapsules, optionally with one or more carriers or diluents.
In the pharmaceutical compositions according to the present invention, the active principle may also be in the form of an inclusion complex in cyclodextrins, their ethers or their esters.
The preparations and examples are presented below and better illustrate the invention PREPARATION 1 40,000 hemp muscle cells isolated from the human aorta (provider: CLONETICS) were placed in a 35 mm dish in a medium containing 2 ml of DMEM (medium Eagle modified with Dulbecco containing 4.5 g / l of glucose, 3.7 g / l of NaHCO3 and without containing any of L-glutamine or Na pyruvate). 20% v / v of fetal bovine serum was depleted for 30 minutes at 80 ° C, 4 mM of L-giutamine, 50 U / ml of penicillin and 50 μg / ml of streptomycin were added. The cells were left in this medium for a growth period of 3 days before being tested according to the examples given below.
PREPARATION 2 Cell-containing dishes were prepared as described in Preparation 1. Apoptosis was induced by replacing the medium described in Preparation 1 with the same medium containing only 0.2% of fetal bovine serum. The effect of the compounds of the invention on the levels of latent and active TGF-β1 was measured in the extracellular media after 24 hours of contact with the cells, compared with controls (0.2% of fetal bovine serum and 20% of fetal bovine serum). Active TGF-β1 was determined directly in the culture supernatants, but latent TGF-β1 was determined after activation. For activation, 0.5 ml of the culture supernatant was incubated in the presence of 0.1 ml of 1M HCl for 10 minutes at room temperature. The mixture was then neutralized with 0.1 ml of buffer 0.5 M Hepes, which contains 1.2 M NaOH. Determinations of TGF-β1 were made with the help of a specific ELISA test.
PREPARATION 3 Five Sprague Dawley rats (Ifffa Credo, France) weighing approximately 280 g each day for 3 days were treated with the test compound, which was administered orally. After 24 hours of the last forced feeding, the rats were anesthetized. Blood was taken from the abdominal aorta in EDTA, the samples were centrifuged and the supernatants (platelet-rich plasma) were frozen. The diaphragms were also taken, rinsed several times in cold PBS (saline regulated at pH with phosphate) and centrifuged. After an additional ultracentrifugation, the plugs were collected from the PBS and frozen. Determinations of latent and active TGF-β1 were made in the plasma and ground diaphragms using the technique described in preparation 2. The increase in the circulation of latent TGF-β1 levels was recorded in the rats treated with the compounds of the invention compared to the control rats. The increase in the levels of active TGF-β1 in the diaphragms of the rats treated with the compounds of the invention was also recorded.
PREPARATION 4 Plates containing the cells were prepared as in preparation 1. Apoptosis was induced by three different methods: a) replacing the medium of preparation 1 with the same medium containing only 0.2% fetal bovine serum; b) adding increasing doses of NGF (0.01 ng / ml to 100 ng / ml) to the medium described in preparation 1; c) adding increasing doses of vincristine (0.1 pg / ml to 10 ng / ml) to the medium described in preparation 1. Through an ELISA determination test of the mono- and oligo-nucleosomes associated with cytoplasmic histones after washing and Cell lysis, the effects of the compounds of the invention on apoptosis were measured after 24 hours of contact with the cells compared to the levels of apoptosis obtained in the absence of products (maximum level of apoptosis) or in the presence of 20% serum of fetal bovine (minimum level of apoptosis).
EXAMPLE 1 1- (2,2-difen i I t t I) -4 - (3 - 1 r if luorometilf in il) -1, 2,3,6-tetrahydropyridine and its hydrochloride a / 1 - (a, a-di-f-nylacetyl) -4- (3-trifluoromethyl) n-I) -1, 2,3,6-tetrahydropyridine. 8 g of a, a-diphenylacetyl chloride in 50 ml of methylene chloride were added dropwise to a mixture of 8 g (0.035 mole) of 4- (3-trifluoromethylphenyl) -1,2, 3,6-tetrahydropyridine, 50 ml of methylene chloride and 4.96 ml of triethylamine at a temperature of 0 / + 5 ° C. The stirring was carried out for 1 hour at room temperature, the solvent was evaporated under reduced pressure, the residue was taken up in ethyl ether, the washing was carried out with an aqueous solution at 0.2M hydrochloric acid, with water, with an aqueous solution. of sodium carbonate and then with water. Drying was carried out over sodium sulfate, the solvent was evaporated under reduced pressure. 5 g of the title compound were obtained.
1b / 1- (2,2-diphenylethyl) -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine and its hydrochloride. A solution of 5 g (0.012 mol) of the product from the preceding step in 50 ml of ethyl ether was added dropwise to a mixture of 0.7 g of lithium-aluminum hydride in 10 ml of diethyl ether at 25 ° C. The stirring was carried out at room temperature for 1 hour, then 5 ml of water was added dropwise. Two phases were separated, the organic phase was dried over sodium sulfate and the solvent was evaporated under reduced pressure. In this manner, 1- (2,2-diphenylethyl) -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine was obtained. The hydrochloride was prepared with the aid of a saturated solution of hydrochloric acid in diethyl ether. The crystallization was introduced into approximately 150 ml of ethyl acetate. P. f. (207-210 ° C).
EXAMPLE 2 1- [2,2- (4,4'-Dichlorodiphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine and its oxalate. 2a / a, a- (4,4'-dichlorodiphenyl) acetaldehyde. 0.75 g (0.025 mole) of 80% sodium hydride was added in portions to a mixture of 5.5 g (0.025 mole) of trimethylsulfoxonium iodide in 10 ml of anhydrous tetrahydrofuran. The mixture was heated at 55 ° C for 6 hours and 6 g (0.025 mole) of 4,4'-dichlorobenzophenone in 10 ml of anhydrous tetrahydrofuran was added thereto. The mixture was allowed to stir at 55 ° C overnight, was emptied into water, extracted with ethyl ether, the organic phase was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. The residue was dissolved in 32 ml of toluene and 3 ml of BF3-Et2O was added thereto. The mixture was stirred for 2 minutes and then allowed to stand for 3 minutes. The washing was carried out twice with an aqueous solution of sodium bicarbonate, the organic phase was dried over sodium sulfate, and the solvent was evaporated under reduced pressure. An oil was obtained, which was purified through gel column chromatography eluting with a hexane / ethyl acetate 0 = 9/1 mixture. The title compound was obtained.
2b / 1 - [2, 2- (4,4'-dic lo rod if enyl) ethyl] -4- (3-trifluoromethylf in l) -1,2,3,6-tetrahydropyridine and its oxalate. 1.3 g (0.0045 mol) of the product of the preceding step, 1.2 g (0.0053) or 4- (3-trifluoromethylphenyl) -1, 2.3.6-tetrahydropyridine, 21 ml of methanol, 0.8 ml of glacial acetic acid and 0.5 g were mixed. of anhydrous sodium acetate at the temperature of 0 / + 5 ° C. 0.76 g (0.0121 mole) of sodium cyanoborohydride was added to the mixture at the same temperature, the stirring was carried out for 1.5 hours at low temperature, and then at room temperature overnight. 5 ml of concentrated hydrochloric acid were added dropwise, stirring was continued for 10 minutes, methanol was evaporated and the residue was taken up in a mixture of ethyl acetate / dilute aqueous NH 4 OH solution. The two phases were separated, the organic phase was dried over sodium sulfate and the solvent was evaporated under reduced pressure. An oil was obtained, which was purified through silica gel column chromatography eluting with a hexane / ethyl acetate mixture = 9/1. The title compound was obtained as a base. The oxalate was prepared with the aid of oxalic acid in isopropanol. P. f. (oxalate) 187-189 ° C.
EXAMPLE 3 1- [2,2- (3,3'-Bistrifluoromethyldi) nyl) ethyl] 4- (3-trifluoro methyl n-nyl) -1,2,3,6-tetrahydropyridine and its oxalate. 3a / a, a- (3,3'-bistrifluoromethyldiphenyl) acetaldehyde. It was continued as in Example 2a /, but using 3,3'-bistrifluoromethylbenzophenone, and thus the title compound was obtained.
3 b / 1- [3,3- (3,3'-Bistrifluoromethyldiphenyl) ethyl] -4- (3-trif-Ioromethylphenyl) -1,2,3,6-tetrahydropyridine and its oxalate. It was continued as described in Example 2b /, but using the product of the preceding step in place of a, a- (4,4'-diciorodiphenyl) acetaldehyde, and the title compound was obtained. P. f. (oxalate) 194-196 ° C.
EXAMPLE 4 1 - [2, 2- (4,4'-dimethoxydi-fe n i I) e t i I] -4- (3-trifluoromethyl nyl) -1, 2,3,6-tetrahydropyridine and its hydrochloride. 4a / a, a- (4,4'-dimethoxydifeniI) acetaldehyde. It was continued as described in Example 2a /, but using 4,4'-d i methoxy benzo-fe-none, and the title compound was obtained.
4b / 1 - [2, 2- (4,4'-dimethoxy dif enyl) eti I] -4- (3-trif luoromethylphenyl) -1,2, 2,3,6-tetrahydropyridine and its hydrochloride. It was continued as described in Example 2b /, but using the product of the preceding step instead of < x, a- (4,4'-dichlorodiphenyl) acetaldehyde, and the title compounds were obtained. P. f. (hydrochloride) 214-216 ° C.
EXAMPLE 5 1 - [2 - (4-f Iorofenyl) -2-f-enylethyl] -4- (3-t rif luoromethylphenyl) -1,2,3,6-tetrahydropyridine and its hydrochloride. 5a / a.-4-fluorophenyl-a-phenylacetaldehyde. It was continued as described in Example 2a /, but using 4-fluorobenzophenone, and the title compound was obtained.
5b / 1 - [2, 2- (4-f Iorofenyl) -2-f-enylethyl] -4- (3-trifluoromethyl-phenyl) -1,3,6,6-tetrahydropyridine and its hydrochloride. It was continued as described in Example 2b /, but using the product of the preceding step instead of a, a- (4,4'-dichlorodiphenyl) acetaldehyde, and the title compound was obtained. P. f. (hydrochloride) 206-208 ° C.
EXAMPLE 6 1- (3,3-diphenylpropyl) -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine and its hydrochloride. The procedure was continued as described in Example 1b /, but using commercial 3,3-diphenylpropionic acid (Aldrich, reference D21, 165-6) instead of 2,2-diphenylacetic acid, and the title compound was obtained. P.f. (hydrochloride) 176-178 ° C.
EXAMPLE 7 1- [2,2- (4,4'-Dichlorodiphenyl) ethyl] -4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine and its hydrochloride. It was continued as described in Example 2b /, but using 4- (6-chloropyrid-2-yl) -1, 2,3,6-tetrahydropyridine instead of 4- (3-trifluoromethylphenyl) -1, 2, 3 , 6-tetrahydropyridine, the title compound was obtained. P. f. (hydrochloride) 230-232 ° C.
EXAMPLE 8 1 - [2- (3,4-Diethylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. 8a / 1-bromo-2- (3,4-diethylphenyl) ethane. A mixture of 4.4 g (0.033 moles) of 3,4-diethylbenzene, 50 ml of methylene chloride, 8.8 g (0.044 moles) of bromoacetyl bromide was cooled to 0-5 ° C and 5.0 were added thereto. g (0.037 moles) of aluminum trichloride. The mixture was stirred at 0-5 ° C for 1 hour and then allowed to stand overnight at room temperature. It was poured into a water / ice mixture, extracted with methylene chloride, the organic phase was dried over sodium sulfate and the solvent was evaporated under reduced pressure. 2.9 g (0.011 mole) of the oil thus obtained were mixed with 6 ml (0.057 mole) of trifluoroacetic acid and 6.7 ml (0.057 mole) of triethylsilane and the mixture was heated at 80 ° C for 4 hours. Then a saturated aqueous solution of sodium bicarbonate was added until a basic pH was reached, the extraction was carried out with ethyl ether, the organic phase was dried over sodium sulfate and the solvent was evaporated under reduced pressure. The crude oil thus obtained was purified through silica gel column chromatography eluting with cyclohexane. The title compound was obtained.
8b / 1 - [2- (3,4-Diethylphenyl) ethyl] -4- (3-trifluoromethyl-p-n-I) - 1, 2, 3,6-tetrahydropyridine hydrochloride. A mixture of 2.6 g (0.001 mole) of 4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine, 60 ml of butanol, 4.1 g (0.025 mole) of anhydrous potassium carbonate in stripes and 2.6 g ( 0.00113 moles) of the product from the preceding step was brought to reflux for 5 hours. The solvent was evaporated under reduced pressure, taken up in ethyl acetate, washed with water, dried over sodium sulfate and the solvent was evaporated under reduced pressure. The oil hydrochloride thus obtained was prepared by treatment with a saturated solution of hydrochloric acid in isopropanol. 1.6 g of the title compound were obtained, P. f. 220-222 ° C.
EXAMPLE 9 > 1 - [2 - (3-methyl-4-pentylphenyl) eti I] -4- (3-trif luoromethylphenyl) -1, 2, 33,6-tetrahydropyridine and 1 [2- (4-methyl-3- pentylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine and its oxalates. 9a / 1-methyl-2-pentylbenzene. 4.7 g (0.035 mole) of phthalic aldehyde were added dropwise to a solution of 50 ml (0.1 mole) of a 2M n-butylmagnesium chloride solution in THF under a nitrogen atmosphere. The mixture spontaneously was heated to 40-45 ° C. The stirring was carried out at room temperature for 1 hourThe mixture was poured into a saturated ammonium chloride solution, extracted with ethyl ether, washed with water, dried over sodium sulfate and the solvent was evaporated under reduced pressure. The oil thus obtained was purified by silica gel column chromatography eluting with a cyclohexane / ethyl acetate = 7/3 mixture.
The product having the highest Rf was isolated. 2.0 g of oil were obtained. The crude reaction mixture was dissolved in 25 ml of ethanol and 1 ml of concentrated sulfuric acid and 0.15 g of 10% Pd / C were added thereto. The hydrogenation was carried out at room temperature for 7 hours. The catalyst was filtered, the solvent was evaporated under reduced pressure and the residue was taken up in ethyl acetate. The mixture was washed with an aqueous solution of sodium bicarbonate, dried and the solvent was evaporated under reduced pressure. 1.35 g of the title compound were obtained.
9b / 1-bromo-2- (3-methyl-4-pentylphenyl) ethane and 1-bromo-2- (4- (4-methyl-3-pentyl Ifen i I) ethane A mixture of 1.17 g (0.0054 moles) of the product from the preceding step, 0.62 ml (0.0072 mole) of bromoacetyl bromide was cooled to 0-5 ° C and 0.81 g (0.006 mole) of aluminum trichloride was added thereto. 5 ° C for 1 hour and then for 4 hours at room temperature The mixture was emptied on ice, the two phases were separated, the organic phase was washed with water, dried and the solvent was evaporated under reduced pressure. dissolved in 2.9 ml of trifluoroacetic acid and 3.1 ml (0.0267 mol) of triethylol was added thereto if not and the mixture was heated at 80 ° C. for 5 hours.It was emptied in an aqueous solution of sodium bicarbonate The mixture was extracted with ethyl ether, washed with water and dried over sodium sulfate, obtaining a mixture of the title compounds.
9c / 1- [2- (3-methyl-4-pentylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine and 1 - [2- (4-methyl-3-pentylphenyl) ) ethyl] -4- (3-trif I uorometi Ifeni I) -1, 2, 3,6-tetrahydrate and its oxalates. A mixture of 0.7 g (0.0031 mol) of 4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine, 16 ml of butanol, (0.0065 of anhydrous potassium carbonate in bars and the product obtained in the previous step (0.0054 mole theory) was refluxed for 6 hours.The solvent was evaporated under reduced pressure, the residue was taken up in ethyl acetate, washed with water, dried over sodium sulfate and the solvent was evaporated under pressure. The oil thus obtained was purified through silica gel column chromatography eluting with a mixture of cyclohexane / ethyl acetate = 7/3 Two products were isolated having similar Rfs.The product having the highest Rf corresponds to 1 - [2- (3-methyl-4-pentylphenyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine The oxalate was prepared in acetone 0.12 g of the product was obtained. f 140-143 ° C. The product having the lowest Rf corresponds to the isomer 1- [2- (4-methyl-3-pentyl nyl] -4- (3- trifluoro methylphenyl) -1, 2,3,6-tetrahydropyridine. The oxalate was prepared in acetone. The crystallization of the product was carried in acetone. 0.08 g of the product were obtained. P.f. 167-169 ° C.
EXAMPLE 10 1- [2- (3,4-Diethylphenyl) -4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine hydrochloride 10a / (1-benzyl 1-1, 2 , 3,6-tetrah id rop i rid-4-il) tributyl stanalate.
A mixture of 15.85 g (0.0837 moles) of 1-benzyl-4-piperidone in 140 ml of anhydrous dimethoxyethane and 25 g (0.0837 moles) of trisylidrazine in 140 ml of anhydrous dimethoxyethane was stirred at room temperature for 3 hours. The solvent was evaporated under reduced pressure. The residue was taken up in 420 ml of anhydrous hexane and 420 ml of anhydrous tetramethylene-ethylene diamine were added thereto. The mixture was cooled to -78 ° C and 156 ml of n-butyl (0.25 moles) (1.6M solution in hexane) were added dropwise thereto. After about 30 minutes, the temperature was allowed to reach 0 ° C and the stirring was carried out for 15 minutes. Then, 45 ml (0.167 moles) of tributylstannyl chloride was added to the reaction mixture. After one hour, a water / ice mixture was added with extreme caution. The extraction was carried out with ethyl ether, the organic base was washed with water, dried over sodium sulphate and the solvent was evaporated under reduced pressure. 70 g of the crude product were obtained, which were purified through silica gel column chromatography eluting with a cyclohexane / ethyl acetate = 95/5 mixture. The title compound was obtained with an oil. 'H-NMR (CDCl 3) -d (ppm): 0.84 (9H; m: CH3); 1.19-1.58 (18H; m: chains); 2.31 (2H; m); 2.53 (2H; m); 3.02 (2H; m); 3.56 (2H; s: benzylic methylene); 5.76 (1H; m *); 7.18-7.41 (5H; m: arom.) * Sidebands3Jcis (1H-117Sn) and 3Jcls (1H-119Sn).
10b / 1-benzyl-4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine. 18.5 g (0.04 mole) of the compound of the preceding step was dissolved in 200 ml of anhydrous dimethylformamide under a nitrogen atmosphere. 11.8 g (0.08 mole) of 2,6-diclopyridine, 0.64 g of Pd (ll) (Ph3P) 2- 438 g (0.04 mole) of tetramethylammonium chloride and 2.76 g (0.02 mole) of carbonate were added to the solution. potassium. The mixture was heated at 110 ° C for 6 hours and then emptied into 100 ml of a 5% sulfuric acid solution. The extraction was carried out with ethyl ether, ammonium hydroxide was added to the aqueous phase until a basic pH and the extraction was carried out with ethyl acetate. The combined organic phases were dried over sodium sulfate and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with a mixture of cyclohexane / ethyl acetate = 1/1. The title compound was obtained. P.f. 100-102 ° C.
10c / 4- (6-chloropyrid-2-yl) -1,2,3,6-tetrahydropyridine hydrochloride.
A solution of 7.0 g (0.024 mole) of the compound from the preceding step in 110 ml of dichloroethane was cooled to 0-5 ° C and 5.8 ml (0.054 mole) of chloroethyl chloroformate was added thereto. The stirring was carried out for 5 minutes and then refluxed for 1.5 hours. The solvent was evaporated under reduced pressure, the residue was taken up in 100 ml of methanol and heating under reflux was carried out for 1 hour. The solvent was evaporated, the residue was taken up in isopropanol and the solid was filtered. The title compound was obtained, which was crystallized in 90% ethane. P. f. 305-307 ° C.
10d / hydrochloride of 1 - [2- (3,4-d-Iei Ifen i I) etl] -4- (6-chloropyrid-2-i I) -1,2,3,6-tetrahydropyridine We proceeded as described in Example 8B / but using the product of the preceding step in place of 4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine, and the title compound was obtained. P. f. 234-236 ° C.
EXAMPLE 11-20 The procedure was continued as described in Example 9, but using the appropriate magnesium halide, and the following compounds were obtained: 1- [2- (3-et i I -4-methylphenyl) ethyl] -4 - (3-t rif luoromet ilf eni I) - 1,2, 3,6-tefrahydropyridine - Ex. 11 1- [2- (4-ethyl-3-methylf eni I) et i I] -4 - (3 - 1 rif luoromethylphenyl) - 1,2, 3,6-tetrahydropyridine - Ex. 12 1- [2- (3-ethyl-4-propylphen i I) ethyl] -4- (3-t rif I uoro methylphenyl) ) - 1, 2,3,6-tetrahydropyridine - Ex. 13 1 - [2- (4-ethyl-3-propylf in ii) eti l] -4- (3-trif luoromethyl in i 1) -1, 2 , 3,6-tetrahydropyridine - Ex. 14 1- [2- (3-butyl-4-met i If in i I) et i I] -4- (3-trifluoromethylmethyl) -1, 2 , 3,6-tetrahydropyridine - Ex. 15 1- [2- (4-Buty! -3-methylphenyl) ethyl] -4- (3-trifluoromethyphenyl) -1,2,3,6-tetrahydropyridine - Ex. 16 1- [2- (3-isobutyl-4-methylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine - Ex. 17 1- [2- (4-isobutyl-3 -methylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine - Ex. 18 1- [2- (3-isobutyl-4-ethylphenyl) ethyl] -4- (3-trifluoromethylphenyl) ) -1, 2,3,6-tetrahydropyridine - Ex. 19 1- [2- (4-isobutyl-3-ethylphenyl) ethyl] -4- (3-trif luoromethylphenyl) -1, 2,3,6- tetrahydropyridine - Ex. 20
EXAMPLE 21 1- [2 - (6-methyl-3-bi-phenyl-n-ethyl) -4- (3-trifluoromethyl-phenyl) -1, 2, 3,6-tetrah id rop i ridine. It was continued as described in Example 9, but using phenyllithium instead of n-butylmagnesium chloride, and the title compound was obtained.
EXAMPLE 22 1 - [2- (3'-Chloro-biphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-p-n-I) -1, 2, 3, 6-tetrahydropyridine hydrochloride. 22a / 1-bromo-2- (3'-chlorobiphenyl-4-yl) ethanone. A mixture of 5 g (0.026 moles) of 3-chlorobiphenyl, 50 ml of methylene chloride, 6.95 g (0.034 moles) of bromoacetyl bromide was cooled to 0-5 ° C and 4 g (0.030) were added thereto. moles) of aluminum trichloride. The stirring was carried out for 1 hour at 5 ° C and then 4 hours at room temperature. The mixture was poured into a water / ice mixture, extracted with methylene chloride, the organic phase was washed with a solution of IN HCl, drying was carried out over sodium sulfate and the residue was evaporated under reduced pressure. 4.5 g of the title compound were obtained. P. f. 63-65 ° C.
22b / 1 - [2- (3'-chlorobiphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride. A mixture of 0.4 g (0.013 moles) of the product from the previous step, 2.95 g (0.013 moles of -4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine, 80 ml of ethanol and 2.32 g (0.0167 moles) ) of anhydrous potassium carbonate in bars was brought to reflux for 1 hour.The salts were removed by filtration and the solution was acidified by the addition of a saturated solution of hydrochloric acid in ethanol.The concentration was carried out under pressure reduced until 40 ml of the residue was allowed to stand overnight at 40 ° C. The precipitate was filtered, washed with water and then with isopropanol, 4.9 g of the title compound were obtained, P. f 217-220 ° C. .
EXAMPLE 23 1 - [2- (2'-Chloro-biphen-yl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-p-n-I) - 1, 2, 3, 6-tetrahydropyridine hydrochloride. It was continued as described in Example 22, but using 2-chlorobiphenyl instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 200-202 ° C (crystallized from isopropanol).
EXAMPLE 24 Hydrochloride of. 1 - [2- (4'-Chlorobiphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine. It was continued as described in Example 22 but using 4-chlorobiphenyl instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 210-215 ° C.
EXAMPLE 25 1 - [2- (4-Isobutylphenyl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 22 but using 4-isobutylbenzene instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 224-228 ° C (crystallized from isopropanol).
EXAMPLE 26 1 - [2- (4-Phenoxyphenyl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 22, but using diphenyl ether instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 205-210 ° C.
EXAMPLE 27 1- [2- (4-Cyclohexylphenyl) -2-oxoethyl] -4- (3-trifluoromethyl-p-n-i) -1, 2, 3, 6-tetrahydropyridine hydrochloride. It was continued as described in Example 22, but using cyclohexylbenzene instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 209-213 ° C (crystallized from isopropanol).
EXAMPLE 28 1 - [2- (4'-F-luorobiphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 22, but using 4-fluorobiphenyl instead of 3-chlorobiphenyl, the title compound was obtained. P. f. 123-125 ° C (crystallized from isopropanol).
EXAMPLE 29 1 - [2- (Biphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 22, but using biphenyl instead of 3-chlorobiphenyl, the title compound was obtained. P. f. 145-147 ° C (base); P. f. (240-243 ° C (hydrochloride).
EXAMPLE 30 Hydrochloride 1 - [2- (4-n-butylphenyl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine. The procedure was continued as described in Example 22, but using 4-n-butylbenzene instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 218-221 ° C.
EXAMPLE 31 1 - [2- (4-t-Butylphenyl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 22, but using 4-t-butylbenzene instead of 3-chlorobiphenyl, and the title compound was obtained. P. f. 97-99 ° C (base).
EXAMPLE 32 1 - [2- (3,4-Diethylphenyl) -4- (3-trif luoromethylf en il) -1, 2,3,6-tetrahydropyridine hydrochloride was continued as described in Example 22, but using 2, 4-Diethylbenzene in place of 3-chlorobiphenyl, the title compound was obtained, P.F. 232-234 ° C.
EXAMPLE 33 1 - [2 - (2 '-trif Ioromethyl bif in yl-4-yl) -2-oxoethyl) -4- (3-trifluoromethyl-phenyl) -1, 2, 3, 6-tetrahydropyridine hydrochloride . 33a / 2- (4-bromophenyl) -2,2-dimethoxyethane. A mixture of 2 g (0.01 mol) of 4-bromoacefenone, 5.6 ml of trimethyl orthoformate, 5.6 ml of methanol and 0.67 g of Amberlite® IR 120 was refluxed for 3 hours. After cooling, it was filtered through Celite® and the filtered solution was evaporated. 2.4 g of the title compound was obtained as an oil.
33b / 2,2-dimethoxy-2- (2'-trifluoromethylbiphenyl-4-yl) ethane.
A mixture of 4.9 g (14 moles) of the product from the preceding step, 2.45 g (16 mmoles) of 2-trifluoromethylbenzeneboronic acid, 63 mg (0.28 mmoles) of palladium acetate, 4.84 g (35 mmoles) of potassium carbonate and 4.5 g (14 mmol) of tetrabutylammonium bromide in 19 ml of water was stirred at 70 ° C for 1 hour. It was allowed to cool and extracted with ethyl acetate. The organic phase was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The title compound was obtained as an oil.
33c / 4- (2-trifluorophenyl) acetophenone. A solution of 4 ml of trifluoroacetic acid and 4 ml of water was added to a solution of 4.6 g (0.0105 mol) of the product from the preceding step in 4 ml of methylene chloride at 0 ° C. The mixture was stirred at room temperature for 2 hours, poured into water and extracted with methylene chloride. The organic phase was dried, filtered and the solvent was evaporated under reduced pressure. The crude was purified through silica gel column chromatography eluting with a cyclohexane / ethyl acetate = 9/1 mixture. 1.97 g of the title compound were obtained.
33d / -bromo-4- (2-trifluoromethylphenyl) acetophenone. 0.38 ml (7.5 mmol) of bromide was added dropwise to a solution of 1.97 g (7.5 mmol) of the product from the preceding step in 5.4 ml of methanol, at a temperature of 0 ° C. The stirring was carried out at room temperature for 3 hours, the solvent was evaporated and the residue was taken up in water and extracted with ethyl acetate. The organic phase was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The title product was obtained as an oil.
33e / 1 - [2- (2'-trifluoromethylbiphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride. A solution of 0.74 g (0.0028 moles) of 4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine, 14 ml of ethanol and 1.27 g (0.0092 mol) of anhydrous potassium carbonate in grid was brought to reflux for 1 hour. A solution of 1.2 g (0.0035 mol) of the oil from the preceding step in 3 ml of ethanol was added thereto and the mixture was left under reflux for 30 minutes. The salts were removed by filtration, and the solution was acidified through the addition of a 1M aqueous hydrochloric acid solution. The solvent was evaporated under reduced pressure, the extraction was carried out with chloroform and the organic phase was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The base was freed with the aid of a concentrated ammonia solution and extracted with ethyl acetate, the product was purified by silica gel column chromatography eluting with a cyclohexane / ethyl acetate = 8/2 mixture. The title compound was obtained. The hydrochloride was prepared with the aid of a saturated solution of hydrochloric acid in isopropanol. P. f. 195-197 ° C.
EXAMPLE 34 1 - (2- (3'-trifluoromethylbifen i-4-yl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. proceeded as described in Example 33, but using 3-trifluoromethylbenzeneboronic acid in place of 2-trifluoromethylbenzeneboronic acid in step 33b / the title compound was obtained.P.F.232-234 ° C.
EXAMPLE 35 1 - [2- (4'-trifluoromethylbiphenyl-4-yl) -2-oxoethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 33, but using 4-trifluoromethylbenzeneboronic acid in place of 2-trifluoromethylbenzeneboronic acid in step 33b /, and the title compound was obtained. P. f. 245-247 ° C.
EXAMPLE 36 A mixture of 12.5 g of 2- (2-bromoethyl) naphthalene, 14 g of 4- (3-tpfluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride, 4.34 g of sodium hydroxide, 135 ml of Water and 95 ml of 35% ethanol was heated for 5 hours under reflux, and the reaction mixture was allowed to cool overnight at room temperature. The mixture
^ cooled below 25 ° C. and then filtered, the product thus isolated was washed with water and then dried under vacuum at 50 ° C. The base 1- [2- (2-naphthyl) ethyl] -4- (3-tri fluoro methyl n-nyl) -1.2, 3,6-tetrahydro pyridine was thus obtained in a yield of 90% calculated on the 4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine hydrochloride starting material.
EXAMPLE 37 A mixture of 19.5 g of crude 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride, 95 ml of absolute ethanol and 4.65 ml of 35% hydrochloric acid was heated under reflux with stirring until complete dissolution, and then allowed to cool while stirring was continued. When the first crystals began to form (around 63 ° C) the stirring was stopped and the reaction mixture was kept at 0-5 ° C overnight. After filtration, the product was swelled twice in 30 ml of absolute ethanol, and then dried overnight at 40 ° C under vacuum. Under these conditions, 12.8 g of Form I of 1- [2- (2-naphthyl) ethyl] -4- (3-trif luoromethyl-phenyl) -1,2,3,6-tetrahydroxy-pyridine hydrochloride were obtained. . The differential calorimetric analysis of Form I obtained from this preparation shows a solid-solid transition temperature of 148-149 ° C, a transition enthalpy of 26.4 J / g.
EXAMPLE 38 A mixture of 70 g of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride and 1 liter of absolute ethanol was brought to reflux in a Mettier RC1 calorimeter reactor equipped with an impeller with a diameter of 8 cm until the dissolution of the product is complete. The solution thus obtained was cooled with a cooling rate of 80 ° C per hour and an agitation speed of 500 r.p.m. at 10 ° C. The precipitate thus obtained is filtered and dried overnight at 45 ° C under vacuum. Under these conditions, Form II of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride was obtained. The differential calorimetric analysis of Form II obtained in this preparation shows a solids-solid transition temperature of 153-155 ° C and a transition enthalpy of 24.1 J / g.
EXAMPLE 39 A mixture of 2 g of 1 - [2- (2-naphthyl) ethyl] -4- (3-trif luoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride and 50 ml of dimethylsulphoxide was carried at reflux until complete dissolution, allowed to cool overnight, and then the crystalline product was recovered and dried under vacuum at 45 ° C overnight. Under these circumstances, Form lll of 1- [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylf en il) -1, 2, 3, 6-tet rahidropi ridine hydrochloride was obtained. The differential calorimetric analysis of Form III obtained in this preparation shows: - a solid-solid transition temperature of 141-142 ° C, a transition enthalpy of 17.6 J / g.
EXAMPLE 40 A mixture of 100 g of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride in 1 liter of an ethanol / water mixture , 90/10, was brought to reflux with stirring until the dissolution of the product was completed. The product thus obtained was cooled from the reflux temperature to 5 ° C under impeller stirring at 400 rpm at a cooling rate of 10 ° C / hour. The crystalline product thus obtained was filtered and dried at 45 ° C under vacuum overnight. Under these conditions, 1- [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -112,3,6-tetrahydropyridine hydrochloride was obtained as a mixture of Form l / Form III , in a ratio of 65.7 / 34.3. The differential calorimetric analysis of Form l / lll obtained in this preparation shows a thermogram, which presents only the two characteristic peaks corresponding to Forms I and 111.
EXAMPLE 41 A solution of 3 g of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride in 300 ml of ethanol was atomized in an apparatus of "Büchi mini Spray Dryer" according to the principle of atomization through a parallel current pipe, to regulate the flow rate of the pump, the suction, the heating and the current flow in order to obtain a temperature input of 172 ° C, an outlet temperature of 107 ° C and a depression of 40 mbar. Under these conditions, a broad DSC monopic product was obtained with the maximum at 145 ° C. The particles obtained are spherical and the very homogeneous population did not exceed an average size of 5 micrometers.
EXAMPLE 42 24 kg of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride, Form I / MI, described in Example 40, introduced into the micronization chamber (diameter of 200 mm) of an Alpine 200 AS micronizer at a rate of 25 kg / hour and a working pressure of 6.5 bar and the product thus micronized was recovered in 1 filter sleeve. In this way a micronized product was obtained, which had a particle distribution according to which all the particles have a size smaller than 20 microns and 85% of the particles have a size smaller than 10 microns. The differential calorimetric analysis of the micronized product thus obtained shows that the transition temperatures are not affected by micronization. These transitions are of the solid-solid type. The compound degrades before melting, which starts at 250 ° C.
EXAMPLE 43 A pharmaceutical composition containing, as an active principle, the
Form I / III of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride (micronized) according to Example 42 : Active ingredient 1,192 mg Maize starch 141,208 mg Microcrystalline cellulose 26,000 mg Colloidal silica Anhydrous 0,200 mg Magnesium stearate 0.400 mg The active substance was sieved to 0.2 mm, and then premixed with the excipients. This mixture was sieved at 0.315 mm, mixed again and then sieved again at 0.315 mm. After final mixing, the composition was filled into No. 3 gelatin capsules, at a rate of 170 mg of the composition containing an amount of 1 - [2- (2-naphthyl) ethyl] -4- hydrochloride ( 3-trifluoromethyl faith or I) - 1, 2, 3, 6-tetrahydropyridine-Form l / lll, corresponding to 2 mg of base 1- (2- (2-naphthyl) ethyl] -4- (3- tri fl uoromethyl faith nyl) -1, 2, 3, 6-tetrahydropyridine.
EXAMPLE 44 Cell-containing dishes were prepared as in preparation 1. The levels of TGF-β1 were measured as described in preparation 2. The levels of active TGF-β1 were measured in the extracellular media in the presence of SR 57746A after 1 , 3, 14, 24 and 48 hours and 7 days of contact with the cells, compared with the controls (0.2% of fetal bovine serum, and 20% of fetal bovine serum) through the method described in preparation 2 SR 57746 induces a significant increase in the levels of TGF-β1 activated in the extracellular medium after 14 hours of contact with the cells.
EXAMPLE 45 Cell-containing dishes were prepared as in preparation 1, and apoptosis was induced as in preparation 4 according to method a). The anti-apoptotic effects of SR 57746 and compounds A, B, C, D, E, and F were measured after 1, 2, 14, 24, 48 hours and 7 days of contact with the cells compared to controls (0.2% fetal bovine serum and 20% fetal bovine serum) through the method described in preparation 4. The tested compounds significantly inhibit apoptosis induced by serum deprivation after 24 hours of contact with the cells and for 7 days at least.
EXAMPLE 46 Plates containing cells were prepared as in preparation 1. Apoptosis was induced according to method b). From preparation 4. The levels of apoptosis were measured after 24 hours of contact with the cells through the method described in preparation 4; the same controls as in preparation 4, were used. SR 57746, as well as A, B, C, D, E, and F significantly inhibited the pro-apoptotic effect of NGF.
EXAMPLE 47 Cell-containing dishes were prepared as described in preparation 1. Apoptosis was induced according to method c) of preparation 4. The levels of apoptosis were measured after 24 hours of contact with the cells through the method described in Preparation 4; the same controls were used as in preparation 4. SR 57746 and compounds A, B, C, D, E and F significantly inhibit the pro-apoptotic effect of vincristine.
EXAMPLE 48 1-1- [2- (6,7-Methylenedioxinaphth-2-yl) ethyl] -4- (3-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride. 1.1 g (0.0048 mole) of 2- (6,7-dimethoxynaphth-2-yl) acetic acid, 20 ml of methylene chloride, 2 ml (0.0144 mole) of triethylamine, 1.35 g (0.0048 mole) were stirred at room temperature. of 4- (3-trifluoromethylphenyl) -4-piperodonol and 2.15 g (0.0048 moles) of BOP. The washing was carried out with a 1N HCl solution, and then with a saturated solution of NaHCO3 and then with water. The drying was carried out over sodium sulphate and the solvent was evaporated under reduced pressure. The oil thus obtained, 1.5 g, was dissolved in 18 ml of THF. The mixture was heated to reflux and a solution of 0.97 ml (0.0102 mole) of dimethyl sulfide / borane in 12 ml of THF was added dropwise thereto. The mixture was refluxed for 4 hours, cooled to 0 ° C and 15 ml of methanol was added. Again, it was refluxed for 30 minutes, and then evaporated under reduced pressure. The residue was taken up in ethyl acetate, washed with water, dried over sodium sulfate and evaporated under reduced pressure. The oil obtained was dissolved in 22 ml of glacial acetic acid and 1.2 ml of concentrated sulfuric acid was added thereto, and the mixture was heated at 60 ° C for 4 hours. This was poured into an ice / NaOH mixture and extracted with ethyl acetate. The hydrochloride was prepared with the aid of isopropanol saturated with HCl to obtain the title compound P. f. 277-280 ° C.
EXAMPLE 49 49a / 4- (2-trifluoromethyl-phenyl) -1,2,3,6-tetrahydropyridine hydrochloride. A mixture of 2 g (0.0071 mol) of 4- (2-trifluoromethylphenyl) -4-piperidinol (prepared from benzylpiperidone, 2-bromo-1-trifluoromethylbenzene and magnesium and successive hydrogenation), 12 ml of glacial acetic acid and 3 My concentrated sulfuric acid was heated at 100 ° C for 2 hours. It was poured into an ice / NaOH mixture and extracted with methylene chloride. The organic phase was dried and evaporated under reduced pressure. The hydrochloride was prepared with the aid of isopropanol saturated with hydrochloric acid. P. f. 213-215 ° C.
49b / 1 - [2- (biphenyl-4-yl) etl] -4- (2-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. It was continued as described in Example 8b, but using the product of the preceding step in place of 4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine and 1-bromo-2-biphenylylethane in place of the product of the Step 8a, and the title compound was obtained. P. f. 273-275 ° C.
EXAMPLE 50 1 - [2- (4-Cyclohexenylphenyl) ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine hydrochloride. A mixture of 1 g (0.005 mole) of 2- (4-bromophenyl) ethanol, 0.7 g (0.0055 mole) of 1-cyclohexanboronic acid, 25 mg of palladium acetate, 1.73 g (0.0012 mole) of potassium carbonate and 1.61 g (0.005 mole) of tetrabutylammonium bromide in 7 ml of water was stirred at 70 ° C for 3 hours. It was allowed to cool and extracted with ethyl acetate. The organic phase was dried over sodium sulfate, filtered and the solvent was evaporated under reduced pressure. The reaction crude was purified by silica gel column chromatography, eluting with a cyclohexane / ethyl acetate = 7/3 mixture. The title compound was obtained as an oil. A solution of 1.35 g (6.67 mmoles) of the product from the preceding step, 0.93 ml (6.67 moles) of mesyl chloride and 0.5 ml of methylene chloride was cooled to 0.5 ° C. The mixture was stirred at 0 ° C for 30 minutes and then overnight at room temperature. The mixture was poured into water and extracted with methylene chloride. The organic phase was dried and the solvent was evaporated under reduced pressure. The residue was taken up in 8 ml of isopropanol, and 0.64 ml (4.6 mmol) of triethylamine and 0.45 g (1.7 mmol) of 4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine were added thereto. The mixture was refluxed for 4 hours, the solvent was evaporated and washed with water. It was extracted with methylene chloride, the organic phase was dried and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography eluting with a cyclohexane / ethyl acetate = 8/2 mixture. The hydrochloride was prepared with the aid of isopropanol saturated with HCl. In this manner, the title compound was obtained. P. f. 244-245 ° C.
Claims (1)
- CLAIMS The use of a compound of the formula (I): wherein: -Ri represents a halogen or a CF3, an alkyl group of 1 to 4 carbon atoms or alkoxy of 1 to 4 carbon atoms; -And represents a nitrogen atom or a CH group; -Z 'and Z "each represent hydrogen or an alkyl group of 1 to carbon atoms, or one represents hydrogen and the other represents a hydroxy group, or both, together, represent an oxo group; -Z represents: * a radical phenyl; * monosubstituted with a substituent X, X being: a) an alkyl group of 1 to 6 carbon atoms; alkoxy of 1 to carbon atoms; carboxy alkyl of 3 to 7 carbon atoms; alkoxycarbonyl of 1 to 4 atoms carbon-alkyl of 1 to carbon atoms, carboxyalkoxy of 3 to 7 carbon atoms, alkoxy carbonyl of 1 to 4 carbon atoms-alkoxy of 1 to carbon atoms, b) a group selected from the group of cycloalkyl of 3 to atoms carbon, cycloalkyloxy of 3 to 7 carbon atoms, cycloalkylmethyl of 3 to 7 carbon atoms, ciloalquilamino 3 to 7 carbon atoms and cyclohexenyl, it being possible for said group to be substituted by a halogen, hydroxy, alkoxy of 1 to 4 carbon atoms, carboxy, alkoxycarbonyl from 1 to 4 át carbon, amino, mono or dialkylamino of 1 to 4 carbon atoms; one group selected from phenyl, and phenoxy, phenylamino, n-alkylphenylamino 1 to 3 carbon atoms, phenylmethyl, phenylethyl, phenylcarbonyl, phenylthio, phenylsulfonyl, phenylsulfinyl or styryl, it being possible for said group to be mono- or poly-substituted in the group phenyl with a halogen, CF3, alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, cyano, amino, mono or dialkylamino of 1 to 4 carbon atoms, acylamino of 1 to 4 carbon atoms, carboxy alkoxycarbonyl of 1 to 4 carbon atoms, aminocarbonyl, mono- or dialkylamino of 1 to 4 carbon atoms, aminoalkyl of 1 to 4 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms or haloalkyl of 1 to 4 carbon atoms; * A phenyl radical disubstituted with R2 substituent, R2 being a halogen or a hydroxy, methyl, ethyl, alkyl of 3 to 6 carbon atoms, alkoxy of 1 to 4 carbon atoms, or trifluoromethyl, and with a substituent X, X being defined as above: * a 1-naphthyl or 2-naphthyl radical; * a 1-naphthyl or 2-naphthyl radical substituted at positions 5, 6, 7 and / or 8 with 1 or 2 hydroxyl groups, one or . • two alkoxy groups of 1 to 4 carbon atoms or a 6,7-methylenedioxy group; -o Z "is hydrogen and Z and Z 'represent, each independently, an unsubstituted or mono, di or trisubstituted phenyl group, or one of its pharmaceutically acceptable salts or solvates, for the preparation of pharmaceutical compositions capable of increasing the circulation and cellular and extracellular levels of TGF-β1 2. The use according to claim 1, wherein said compound of formula (I), Y is CH and RT is o- or m-CF3. - The use according to claim 2, wherein Z 'and Z "are hydrogen 4. The use according to claim 2, wherein Z 'and Z" together form an oxo group and Z is 4-biphenyl. 5. The use according to claim 3, wherein Z represents a 2-naphthyl, 6,7-dimethoxy-2-naphthyl or 6,7-metlenedioxy-2-naphthyl group. 6. The use according to claim 3, wherein Z represents a monosubstituted phenyl radical with a substituent X, X being as defined in claim 1. 7. The use according to claim 3, wherein Z represents a phenyl radical monosubstituted with a group X ', X' being an unsubstituted or substituted by 1 to 3 halogens, 1 to 3 is CF3, 1 to 3 alkyl of 1 to 4 carbon atoms, phenyl 1 to 3 alkoxys of 1 to 4 carbon atoms, 1 to 3 cyans, 1 to 3 amines, 1 to 3 mono or diakylaminos of 1 to 4 carbon atoms, 1 to 3 acylaminos of 1 to 4 carbon atoms, 1 to 3 carboxis, 1 to 3 alkoxycarbonyl of 1 to 4 carbon atoms, 1 to 3 aminocarbonilos, 1 to 3 mono- or dialkylamino carbonyl 1 to 4 carbon atoms, 1 to 3 aminoalkyl of 1 to 4 carbon atoms, 1 to 3 hydroxyalkyl of 1 to 4 carbon atoms of carbon or 1 to 3 haloalkyl groups of 1 to 4 carbon atoms; or a disubstituted phenyl radical with a substituent R2, R2 being as defined in claim 1 and with a substituent X ', X' being as defined above. 8. The use according to claim 3, wherein Z is a phenyl group disubstituted at positions 3 and 4 with a methyl, ethyl, alkyl group of 3 to 6 carbon atoms. 9. The use according to claim 2, wherein Z "is hydrogen and Z and Z ', each one representing a phenyl group, a phenyl group substituted at the 2, 3 or 4 position with a fluorochloro atom or with methyl, ethyl, n-propyl, i-butyl, n-butyl, i-butyl, s-butyl, t-butyl, trichloromethyl, cyano, methoxy, methylthio, methylsulphonyl, ethoxy, ethylthio, ethylsulphonyl, alkoxycarbonyl group 1 3 carbon atoms dialkylaminocarbonyl of 1 to 3 carbon atoms, a phenyl group disubstituted in positions 2,4, 3,4, 3,5 or 2,6 with a chlorine or fluorine atom, or with a methyl, ethyl group , trifluoromethyl, cyano or methoxy, or a phenyl group trisubstituted at the 3,4,5, 2,4,5 or 2,4,6 positions with a chlorine or fluorine atom, or with a methyl, ethyl, trifluoromethyl group, cyano or methoxy 10. The use according to claim 3, wherein the compound of the formula (I) is 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) - hydrochloride 1,2,3,6-tetrahydropyr 11. The use according to claim 10, wherein the hydrochloride of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoro-methyl-en-I) -1,3, 6-tetrahydropyridine is atomized or micronized. 12. The use according to claim 10, wherein the hydrochloride of 1 - [2- (2-naphthyl) ethyl] -4- (3-trifluoromethylphenyl) -1, 2,3,6-tetrahydropyridine is a mixture micronized crystalline forms I and III in a ratio of approximately 66/34. 13. The use according to one of claims 1 to 12, wherein the pharmaceutical compositions are indicated for the treatment of diseases that can be treated by increasing the circulation and cellular and extracellular levels of TGFßl. 14. The use according to claim 3, wherein the pharmaceutical compositions are indicated for the treatment of diseases selected from pathologies related to an abnormal apoptotic activity; eye diseases such as cataracts or glaucoma; osteoporosis; Bone fracture; epidermal lesions; restenosis; conditions related to incorrect proliferation or migration of smooth muscle cells; inflammations of the respiratory system; asbestosis; silicosis; lupus erythematosus; Goodpasture syndrome; granulomatosis; eosinophilic granulomatosis; gastric and duodenal ulcers; oseophagitis; enteritis; gastritis; septicemia; malfunctioning of hematopoiesis and / or lymphopoiesis; cystic fibrosis. 15. The use according to claim 13, wherein the pharmaceutical compositions are indicated for the treatment of pathologies related to an abnormal apoptotic activity. 16. The use according to claim 15, wherein the pharmaceutical compositions are indicated for the treatment of a disease selected from cancer and its metastasis; infections by antivirus such as HIV and HITV 1 and 2 and its consequences such as ATL; leukemia; leukemia; myelopathies and arthropathies; hepatitis (C, A, B, F); AIDS; immune deficiencies; cell aging; tissue degeneration phenomenon; inflammation; cell proliferation; infectious diseases; rejection of grafts; acute or chronic rheumatoid arthritis; Ulcerative colitis; thrombocytopenic purpura; autoimmune erythromoclast anemia; juvenile diabetes (Type I) (insulin dependent); myelodysplastic syndrome, Huntington's disease; prion diseases; ARDS; prosthetic hypertrophy; asthma; atherosclerosis and its thrombo-embolic complications; kidney diseases; glomerolunephritis; chronic pancreatitis, autoimmune gastritis, and primary biliary cirrhosis. 17. The use according to claim 16, wherein the pharmaceutical compositions are indicated for the treatment of graft rejection or acute or chronic rheumatoid arthritis. 18. The use according to claim 15, of a compound of the formula (I), other than the compounds wherein Z 'and Z "each represents hydrogen and Z represents 1-naphthyl or 2-naphthyl for the preparation of a drug capable of treating myocardial infarction, myocardial ischemia, coronary vasospasm, angina and heart failure 19.- A compound selected from 1- [2- (6,7-methylenedioxinaphth-2-yl) ethyl] -4- (3-trifluoromethyl nyl) -1, 2,3,6-tet rahydropyrinium, 1- [2- (4-cyclohexenylphenyl) -ethyl] -4- (3-trifluoromethylphenyl) -1,2,3,6- tetrahydropyridine and 1- [2- (b-fe nyl-4-yl) ethyl] -4 - (3-trifluoromethyl-phenyl I) -1, 2,3,6-tetrahydropyridine, and their pharmaceutically acceptable salts or solvates.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/06522 | 1997-05-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99010961A true MXPA99010961A (en) | 2001-09-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5461405B2 (en) | Regulators of cystic fibrosis membrane conductance regulator | |
EP0996443A1 (en) | Certain diarylimidazole derivatives; a new class of npy specific ligands | |
JPH0432821B2 (en) | ||
JP2002501498A (en) | Use of tetrahydropyridine derivatives in the manufacture of a medicament for treating diseases causing demyelination | |
TW201206435A (en) | Piperidinyl compound as a modulator of chemokine receptor activity | |
EP1123702A1 (en) | Analgesics | |
CA2290557C (en) | Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-.beta.1 | |
MXPA99010961A (en) | Use of 4-substituted tetrahydropyridines for making medicines acting on tgf-&bgr;1 | |
KR100549656B1 (en) | Diphenyl alkyl-tetrahydropyridines, process for their preparation, and pharmaceutical composition containing them | |
TW460461B (en) | Substituted phenylamidines for use in fighting or preventing diseases in which smaller or larger cell aggregations occur or cell-matrix interactions are involved, pharmaceutical compositions containing these compounds and processes for preparing them | |
US7297799B2 (en) | Preparation of benzoylalkyl-1,2,3,6-tetrahydropyridines and use thereof | |
MXPA99005108A (en) | 1-phenylalkyl-1,2,3,6-tetrahydropyridines for treating alzheimer's disease | |
PT950048E (en) | 1-PHENYLALQUIL-1,2,3,6-TETRAHYDROPYRIDINES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | |
JPH08268949A (en) | Diphenylmethylene derivative | |
JPH0920664A (en) | Narcotic antagonistic agent | |
MXPA99005621A (en) | Micro-particulate form of a tetrahydropyridin derivative | |
JPH10265384A (en) | Hypercardia suppressant |